Page last updated: 2024-08-02 05:46:57
isavuconazole
Description
isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis. [CHeBI]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 6918485 |
| CHEMBL ID | 409153 |
| SCHEMBL ID | 939038 |
| CHEBI ID | 85979 |
| MeSH ID | M0496090 |
Synonyms (59)
| Synonym |
|---|
| ro-0094815 |
| asp9766 |
| 4-[2-[(1r,2r)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]thiazol-4-yl]benzonitrile |
| benzonitrile, 4-[2-[(1r,2r)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]- |
| isavuconazole |
| bal-4815 |
| bal4815 |
| bal-8557(pro-drug) |
| chebi:85979 , |
| CHEMBL409153 |
| 4-[2-[(1r,2r)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile |
| 4-[2-[(2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile |
| 241479-67-4 |
| 60uto373ke , |
| ro 0094815 |
| unii-60uto373ke |
| bal 4815 |
| isavuconazole [inn] |
| S3722 |
| 4-(2-((2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)-1,3-thiazol-4-yl)benzonitrile |
| isavuconazole [mi] |
| isavuconazole [who-dd] |
| 4-{2-[(1r,2r)-2-(2,5-difluoro-phenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl }-benzonitrile |
| DDFOUSQFMYRUQK-RCDICMHDSA-N |
| 4-{2-[(1r,2r)-2-(2,5-difluoro-phenyl)-2-hydroxy-1-methyl -3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl}-benzonitrile |
| (2r,3r)-3-[4-(4-cyanophenyl)thiazol-2-yl]-1-(1h-1,2,4-triazol-1-yl)-2-(2,5-difluorophenyl)-butan-2-ol |
| CS-3492 |
| DTXSID2058251 , |
| SCHEMBL939038 |
| 4-{2-[(2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl}benzonitrile |
| isavuconazol |
| isavuconazolum |
| 4-(2-((2r,3r)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile |
| AC-31076 |
| HY-14273 |
| isavuconazole (inn) |
| D10750 |
| AKOS027250772 |
| 1286730-05-9 |
| mfcd06407745 |
| J-015363 |
| NCGC00390646-01 |
| bal-4815;ro-0094815 |
| bal-4815;bal4815;bal 4815;ro-0094815;ro0094815;ro 0094815 |
| BCP07587 |
| Q6079042 |
| DB11633 |
| AS-30128 |
| CCG-269093 |
| NCGC00390646-02 |
| EX-A1785 |
| isavuconazole; bal-4815; ro-0094815 |
| 4-(2-((2r,3r)-rel-3-(2,5-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile |
| A899541 |
| bdbm50595118 |
| j02ac05 |
| dtxcid6032069 |
| 2r,3r)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,5- difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol |
| EN300-7401534 |
Roles (3)
| Role | Description |
|---|
| ergosterol biosynthesis inhibitor | Any compound that inhibits one or more steps in the pathway leading to the synthesis of ergosterol. |
| EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of EC 1.14.13.70 (sterol 14alpha-demethylase). |
| orphan drug | Any drug that has been developed specifically for treatment of a rare medical condition, the condition itself being known as an orphan disease. |
Drug Classes (6)
| Class | Description |
|---|
| 1,3-thiazoles | |
| nitrile | A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. |
| difluorobenzene | Any member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying two fluorine atoms. |
| tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
| triazole antifungal drug | Any triazole antifungal agent that has been used for the treatment of fungal infections in humans or animals. |
| conazole antifungal drug | Any conazole antifungal agent that has been used for the treatment of fungal infections in animals or humans. |
Protein Targets (9)
Potency Measurements
Inhibition Measurements
Bioassays (158)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID519513 | Antifungal activity against Candida tropicalis isolates after 48 hrs by CLSI M27-A2 procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID567444 | Antifungal activity against Trichosporon asahii after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID567435 | Antifungal activity against Trichosporon mucoides after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519491 | Antifungal activity against Aspergillus fumigatus isolates after 48 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519517 | Antifungal activity against Aspergillus flavus isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557631 | Fungicidal activity against Rhizopus | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519528 | Antifungal activity against Candida albicans isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID567429 | Antifungal activity against Dipodascus capitatus after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519516 | Antifungal activity against Aspergillus fumigatus isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519465 | Antimicrobial activity against Cryptococcus neoformans var. grubii clinical isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID557627 | Fungicidal activity against Aspergillus flavus | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID559002 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 6.74 mg/kg, sc BID | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID567431 | Antifungal activity against Rhodotorula mucilaginosa after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID558990 | Terminal half life in mouse at 1.6 to 13 mg/kg, sc | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID557608 | Antifungal activity against amphotericin B-resistant Aspergillus terreus by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID557614 | Antifungal activity against Mucor by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519515 | Antifungal activity against Candida krusei isolates after 48 hrs by CLSI M27-A2 procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519527 | Antifungal activity against Scedosporium prolificans isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID567434 | Antifungal activity against Saccharomyces cerevisiae after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519468 | Antimicrobial activity against Cryptococcus gattii by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID567445 | Antifungal activity against Trichosporon mucoides assessed as percent susceptible isolates after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID558995 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 5.35 mg/kg, sc administered as single dose | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID519535 | Antifungal activity against Fusarium sp. isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557633 | Fungicidal activity against Cunninghamella | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID557613 | Antifungal activity against Rhizopus by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519497 | Antifungal activity against Candida albicans isolates after 48 hrs by CLSI M27-A2 procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID567440 | Antifungal activity against Trichosporon jirovecii after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519498 | Antifungal activity against Mucor isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519500 | Antifungal activity against Rhizopus isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519492 | Antifungal activity against Aspergillus flavus isolates after 48 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557617 | Antifungal activity against amphotericin B-resistant Aspergillus terreus hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID558991 | Antifungal activity against Candida albicans FA/6862 infected in mouse assessed as fungal load per gram of kidney at 1.6 to 13 mg/kg, sc measured after 29 hrs postinfection | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID519504 | Antifungal activity against Cunninghamella isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519531 | Antifungal activity against Candida tropicalis isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519467 | Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from non-AIDS patient by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID525544 | Antimicrobial activity against Fonsecaea nubica isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
ISSN: 1098-6596 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID323595 | Antifungal activity against Candida glabrata bloodstream isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
ISSN: 0066-4804 | In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. |
| AID525542 | Antimicrobial activity against Fonsecaea pedrosoi isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
ISSN: 1098-6596 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID519512 | Antifungal activity against Candida glabrata isolates after 48 hrs by CLSI M27-A2 procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519521 | Antifungal activity against Mucor isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557629 | Fungicidal activity against Rhizomucor | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID567437 | Antifungal activity against Trichosporon inkin after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID323594 | Antifungal activity against Candida albicans bloodstream isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
ISSN: 0066-4804 | In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. |
| AID519493 | Antifungal activity against Aspergillus niger isolates after 48 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557628 | Fungicidal activity against Aspergillus niger | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519532 | Antifungal activity against Candida sp. isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557637 | Antifungal activity against Aspergillus niger by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID567426 | Antifungal activity against Rhodotorula mucilaginosa after 7 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID557626 | Fungicidal activity against amphotericin B-resistant Aspergillus terreus | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID567439 | Antifungal activity against Trichosporon jirovecii after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519510 | Antifungal activity against Scedosporium prolificans isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519464 | Antimicrobial activity against Cryptococcus neoformans var. grubii by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID519508 | Antifungal activity against Scedosporium apiospermum isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID535684 | Antibacterial activity against Cryptococcus gattii after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
ISSN: 1098-6596 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID567442 | Antifungal activity against Trichosporon domesticum after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519534 | Antifungal activity against Fusarium sp. isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID567443 | Antifungal activity against Trichosporon asahii after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519501 | Antifungal activity against Rhizopus isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID558998 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 8.12 mg/kg, sc administered as single dose | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID567438 | Antifungal activity against Trichosporon inkin after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID558987 | Antifungal activity against Candida albicans FA/6862 assessed as postantifungal effect at =< 1 time MIC by CLSI M27-A2 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID323597 | Antifungal activity against Candida parapsilosis bloodstream isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
ISSN: 0066-4804 | In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. |
| AID519502 | Antifungal activity against Absidia isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557636 | Antifungal activity against amphotericin B-resistant Aspergillus terreus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID567430 | Antifungal activity against Dipodascus capitatus after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID567446 | Antifungal activity against Trichosporon mucoides assessed as percent susceptible/dose-dependent isolates after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID557618 | Antifungal activity against Aspergillus flavus hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID323599 | Antifungal activity against Candida sp. bloodstream isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
ISSN: 0066-4804 | In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. |
| AID558986 | Antifungal activity against Candida albicans FA/6862 by CLSI M27-A2 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID557621 | Antifungal activity against Absidia hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519466 | Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from AIDS patient by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID535689 | Antibacterial activity against Cryptococcus gattii serotype B after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
ISSN: 1098-6596 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID1817568 | Antifungal activity against pan-azole resistant Aspergillus fumigatus SR47013 harbouring Cyp51A Y121F mutant assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
ISSN: 1520-4804 | Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections. |
| AID519533 | Antifungal activity against Candida krusei isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557607 | Antifungal activity against Aspergillus fumigatus by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID535687 | Antibacterial activity against Cryptococcus neoformans serotype D after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
ISSN: 1098-6596 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID535686 | Antibacterial activity against Cryptococcus neoformans serotype A after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
ISSN: 1098-6596 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID519496 | Antifungal activity against Candida parapsilosis isolates after 48 hrs by CLSI M27-A2 procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519581 | Antifungal activity against Aspergillus terreus isolates after 48 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557609 | Antifungal activity against Aspergillus flavus by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID567436 | Antifungal activity against Trichosporon mucoides after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID567432 | Antifungal activity against Rhodotorula mucilaginosa after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID557611 | Antifungal activity against Rhizomucor by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519470 | Antimicrobial activity against Cryptococcus albidosimilis by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID567441 | Antifungal activity against Trichosporon domesticum after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID559000 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 2.03 mg/kg, sc QID | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID519514 | Antifungal activity against Candida sp. isolates after 48 hrs by CLSI M27-A2 procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557632 | Fungicidal activity against Mucor | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519506 | Antifungal activity against Syncephalastrum isolates assessed as lowest compound concentration that produced complete inhibition of microbial growth after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519469 | Antimicrobial activity against Cryptococcus albidus by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID525190 | Antimicrobial activity against Cryptococcus neoformans by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
ISSN: 1098-6596 | Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. |
| AID519519 | Antifungal activity against Aspergillus terreus isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557616 | Antifungal activity against Aspergillus fumigatus hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519523 | Antifungal activity against Absidia isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519511 | Antifungal activity against Scedosporium prolificans isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519509 | Antifungal activity against Scedosporium apiospermum isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519525 | Antifungal activity against Syncephalastrum isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557619 | Antifungal activity against Aspergillus niger hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID567333 | Antifungal activity against Saccharomyces cerevisiae after 5 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519529 | Antifungal activity against Candida parapsilosis isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID559003 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 13.37 mg/kg, sc QID | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID557620 | Antifungal activity against Rhizomucor hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID535688 | Antibacterial activity against Cryptococcus neoformans serotype AD after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
ISSN: 1098-6596 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID567433 | Antifungal activity against Saccharomyces cerevisiae after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519518 | Antifungal activity against Aspergillus niger isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519520 | Antifungal activity against Aspergillus sp. isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519505 | Antifungal activity against Cunninghamella isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID567425 | Antifungal activity against Rhodotorula mucilaginosa after 7 days by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID557625 | Fungicidal activity against Aspergillus fumigatus | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519530 | Antifungal activity against Candida glabrata isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519522 | Antifungal activity against Rhizopus isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID557612 | Antifungal activity against Absidia by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519536 | Antifungal activity against Fusarium sp. isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519499 | Antifungal activity against Mucor isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID1873196 | Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 mins using [3H]-estrone sulfate as substrate by liquid scintillation counter analysis | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237ISSN: 1768-3254 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. |
| AID323598 | Antifungal activity against Candida tropicalis bloodstream isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
ISSN: 0066-4804 | In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. |
| AID525543 | Antimicrobial activity against Fonsecaea monophora isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
ISSN: 1098-6596 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID557610 | Antifungal activity against Aspergillus niger by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID557622 | Antifungal activity against Rhizopus hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID567447 | Antifungal activity against Trichosporon sp. after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID535685 | Antibacterial activity against Cryptococcus neoformans after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
ISSN: 1098-6596 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID525188 | Antimicrobial activity against Cryptococcus gattii by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
ISSN: 1098-6596 | Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. |
| AID323596 | Antifungal activity against Candida krusei bloodstream isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
ISSN: 0066-4804 | In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. |
| AID519495 | Antifungal activity against Aspergillus sp. isolates after 48 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID525187 | Antimicrobial activity against Cryptococcus gattii by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
ISSN: 1098-6596 | Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. |
| AID567427 | Antifungal activity against Dipodascus capitatus after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID558994 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 0.82 mg/kg, sc QID | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID557615 | Antifungal activity against Cunninghamella by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID535690 | Antibacterial activity against Cryptococcus gattii serotype C after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
ISSN: 1098-6596 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID525189 | Antimicrobial activity against Cryptococcus neoformans by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
ISSN: 1098-6596 | Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. |
| AID557630 | Fungicidal activity against Absidia | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID558996 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 2.67 mg/kg, sc BID | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID525541 | Antimicrobial activity against Fonsecaea isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
ISSN: 1098-6596 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID557634 | Antifungal activity against Aspergillus fumigatus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID567428 | Antifungal activity against Dipodascus capitatus after 4 days by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID519503 | Antifungal activity against Absidia isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID567448 | Antifungal activity against Trichosporon sp. after 4 days by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
ISSN: 1098-6596 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID559001 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 13.48 mg/kg, sc administered as single dose | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID557624 | Antifungal activity against Cunninghamella hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID558989 | Antifungal activity against Candida albicans FA/6862 assessed as postantifungal effect at 5 to 100 times MIC by CLSI M27-A2 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID558992 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 3.27 mg/kg, sc administered as single dose | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID557623 | Antifungal activity against Mucor hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1872531 | Oral bioavailability in monkey relative to control | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231ISSN: 1768-3254 | Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development. |
| AID519524 | Antifungal activity against Cunninghamella isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID519507 | Antifungal activity against Syncephalastrum isolates assessed as lowest compound concentration that produced slight growth or approximately 25% of that of growth control after 24 hrs by CLSI M38-A procedure based assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID558988 | Antifungal activity against Candida albicans FA/6862 assessed as postantifungal effect at 2 times MIC by CLSI M27-A2 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID557635 | Antifungal activity against Aspergillus flavus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1817557 | Antifungal activity against Aspergillus fumigatus ATCC 204305 assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
ISSN: 1520-4804 | Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections. |
| AID558997 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 1.34 mg/kg, sc QID | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID557638 | Plasma concentration in human | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
ISSN: 1098-6596 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID558993 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 1.63 mg/kg, sc BID | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
| AID519526 | Antifungal activity against Scedosporium apiospermum isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
ISSN: 0066-4804 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. |
| AID558999 | Ratio of AUC to MIC in mouse infected with Candida albicans FA/6862 at 4.06 mg/kg, sc BID | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
ISSN: 1098-6596 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. |
Research
Studies (366)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (5.46) | 29.6817 |
| 2010's | 202 (55.19) | 24.3611 |
| 2020's | 144 (39.34) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 37 (9.84%) | 5.53% |
| Reviews | 66 (17.55%) | 6.00% |
| Case Studies | 60 (15.96%) | 4.05% |
| Observational | 3 (0.80%) | 0.25% |
| Other | 210 (55.85%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| 2-(4-methyl-1,3-thiazol-5-yl)ethanol | | 1,3-thiazoles;
primary alcohol | Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-aminothiazole | | 1,3-thiazoles;
primary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| famotidine | | 1,3-thiazoles;
guanidines;
sulfonamide | anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nizatidine | | 1,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phthalylsulfathiazole | | 1,3-thiazoles;
dicarboxylic acid monoamide;
sulfonamide antibiotic;
sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| succinylsulfathiazole | | 1,3-thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulfathiazole | | 1,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiabendazole | | 1,3-thiazoles;
benzimidazole fungicide;
benzimidazoles | antifungal agrochemical;
antinematodal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| niridazole | | 1,3-thiazoles;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methylthiazole | | 1,3-thiazoles | Maillard reaction product | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-aminothiazoline | | 1,3-thiazoles;
primary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-amino-delta(2)-thiazoline-4-carboxylic acid | | 1,3-thiazoles;
amino acid zwitterion;
sulfur-containing amino acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(alpha-thenoylamino)-2-nitro-5-thiazole | | 1,3-thiazoles;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-isobutyl-1,3-thiazole | | 1,3-thiazoles | flavouring agent;
Maillard reaction product;
pheromone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N(4)-acetylsulfathiazole | | 1,3-thiazoles;
acetamides;
sulfonamide | marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| disperse blue 124 | | 1,3-thiazoles;
monoazo compound;
tertiary amine | allergen;
dye;
hapten | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thifluzamide | | 1,3-thiazoles;
anilide fungicide;
aromatic amide;
aromatic ether;
dibromobenzene;
organofluorine compound | antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-aminoethyl)thiazole | | 1,3-thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiamethoxam | | 1,3-thiazoles;
2-nitroguanidine derivative;
organochlorine compound;
oxadiazane | antifeedant;
carcinogenic agent;
environmental contaminant;
neonicotinoid insectide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ritonavir | | 1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas | antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xv 638 | | 1,3-thiazoles;
benzamides;
diazepanone;
diol;
secondary alcohol;
secondary carboxamide;
ureas | HIV protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tiazofurin | | 1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide | antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ravuconazole | | 1,3-thiazoles;
fluorobenzenes;
nitrile;
tertiary alcohol;
triazoles | antifungal drug;
antileishmanial agent;
EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| camalexin | | 1,3-thiazoles;
indole phytoalexin | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-chlorophenyl)-3-[4-methyl-2-(thiophen-2-yl)-1,3-thiazol-5-yl]urea | | 1,3-thiazoles;
monochlorobenzenes;
phenylureas;
thiophenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 387032 | | 1,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefodizime | | 1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefteram pivoxil | | 1,3-thiazoles;
cephams;
oxime O-ether;
pivaloyloxymethyl ester;
tetrazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cystothiazole a | | 1,3-thiazoles;
biaryl;
enoate ester;
enol ether;
methyl ester;
organonitrogen heterocyclic antibiotic | antifungal agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ceftriaxone | | 1,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefetamet pivoxyl | | 1,3-thiazoles;
cephams;
oxime O-ether;
pivaloyloxymethyl ester | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| famotidine | | 1,3-thiazoles;
guanidines;
sulfonamide | anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefotaxime | | 1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| apratoxin a | | 1,3-thiazoles;
apratoxin | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (6R,7R)-7-[[2-(2-amino-4-thiazolyl)-2-hydroxyimino-1-oxoethyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | | 1,3-thiazoles;
cephalosporin;
ketoxime | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s 1006 | | 1,3-thiazoles;
carbamate ester;
carboxylic acid;
cephalosporin;
enamide;
secondary carboxamide | antibacterial drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cinalukast | | 1,3-thiazoles;
carboxylic acid | anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefditoren pivoxil | | 1,3-thiazoles;
cephams;
oxime O-ether;
pivaloyloxymethyl ester | antibacterial drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ixabepilone | | 1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle | antineoplastic agent;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gw 501516 | | 1,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound | carcinogenic agent;
PPARbeta/delta agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dolastatin 10 | | 1,3-thiazoles;
tetrapeptide | animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ppi-0903 | | 1,3-thiazoles;
cephalosporin;
iminium betaine;
organic phosphoramidate;
oxime O-ether;
thiadiazoles | antibacterial drug;
antimicrobial agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mirabegron | | 1,3-thiazoles;
aromatic amide;
ethanolamines;
monocarboxylic acid amide | beta-adrenergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dysidenin | | 1,3-thiazoles;
organochlorine compound;
secondary carboxamide;
tertiary carboxamide | animal metabolite;
marine metabolite;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pateamine a | | 1,3-thiazoles;
macrodiolide;
olefinic compound;
primary amino compound;
tertiary amino compound | antineoplastic agent;
antiviral agent;
eukaryotic initiation factor 4F inhibitor;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| masitinib | | 1,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines | antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethaboxam | | 1,3-thiazoles;
aromatic amide;
aromatic amine;
nitrile;
secondary amino compound;
thiophenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ym 216391 | | 1,3-oxazoles;
1,3-thiazoles;
azamacrocycle;
benzenes;
heterodetic cyclic peptide | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluensulfone | | 1,3-thiazoles;
olefinic compound;
organochlorine pesticide;
organofluorine pesticide;
sulfone | agrochemical;
nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(5-nitrothiazol-2-ylthio)-1,3,4-thiadiazol-2-amine | | 1,3-thiazoles;
C-nitro compound;
organic sulfide;
primary amino compound;
thiadiazoles | antibacterial agent;
c-Jun N-terminal kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lcl161 | | 1,3-thiazoles;
aromatic ketone;
L-alanine derivative;
monofluorobenzenes;
N-acylpyrrolidine | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cobicistat | | 1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclopentylidene-[4-(4-chlorophenyl)thiazol-2-yl]hydrazone | | 1,3-thiazoles;
hydrazone;
monochlorobenzenes | EC 2.3.1.48 (histone acetyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dabrafenib | | 1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mobic | | 1,3-thiazoles;
benzothiazine;
monocarboxylic acid amide | analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxathiapiprolin | | 1,3-thiazoles;
isoxazoline;
N-acylpiperidine;
organofluorine compound;
pyrazoles;
tertiary carboxamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LimKi 3 | | 1,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide | LIM kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clothianidin | | 1,3-thiazoles;
2-nitroguanidine derivative;
clothianidin;
organochlorine compound | environmental contaminant;
neonicotinoid insectide;
nicotinic acetylcholine receptor agonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| althiomycin | | 1,3-thiazoles;
aldoxime;
ether;
gamma-lactam;
pentapeptide;
peptide antibiotic;
primary alcohol;
pyrroline;
secondary carboxamide;
tertiary carboxamide | antibacterial agent;
bacterial metabolite;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clothianidin | | 1,3-thiazoles;
2-nitroguanidine derivative;
clothianidin;
organochlorine compound | environmental contaminant;
neonicotinoid insectide;
nicotinic acetylcholine receptor agonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| colibactin | | 1,3-thiazoles;
azaspiro compound;
polyketide;
pyrroline;
secondary carboxamide | alkylating agent;
carcinogenic agent;
Escherichia coli metabolite;
genotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-cyanopyridine | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-phenyl-3-furoxancarbonitrile | | 1,2,5-oxadiazole;
benzenes;
N-oxide;
nitrile | geroprotector;
nitric oxide donor;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| anastrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bicalutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbonyl cyanide m-chlorophenyl hydrazone | | hydrazone;
monochlorobenzenes;
nitrile | antibacterial agent;
geroprotector;
ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cimaterol | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cimetidine | | aliphatic sulfide;
guanidines;
imidazoles;
nitrile | adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cypermethrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound | agrochemical;
molluscicide;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dichlobanil | | dichlorobenzene;
nitrile | agrochemical;
cellulose synthesis inhibitor;
environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbonyl cyanide p-trifluoromethoxyphenylhydrazone | | aromatic ether;
hydrazone;
nitrile;
organofluorine compound | ATP synthase inhibitor;
geroprotector;
ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fipronil | | (trifluoromethyl)benzenes;
dichlorobenzene;
nitrile;
primary amino compound;
pyrazoles;
sulfoxide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| letrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| milrinone | | bipyridines;
nitrile;
pyridone | cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nilvadipine | | dihydropyridine;
isopropyl ester;
methyl ester;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| periciazine | | hydroxypiperidine;
nitrile;
phenothiazines | adrenergic antagonist;
first generation antipsychotic;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zaleplon | | nitrile;
pyrazolopyrimidine | anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| systhane | | monochlorobenzenes;
nitrile;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chloroacetonitrile | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzyl cyanide | | benzenes;
nitrile | animal metabolite;
pheromone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pirinitramide | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyanamide | | nitrile;
one-carbon compound | EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dicyandiamido | | guanidines;
nitrile | curing agent;
explosive;
fertilizer;
flame retardant;
nitrification inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ricinine | | nitrile;
pyridine alkaloid;
pyridone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toyocamycin | | antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside | antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-cyanophenol | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,3-dicyanobenzene | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenoxylate | | ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine | antidiarrhoeal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ioxynil | | iodophenol;
nitrile | environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enbucrilate | | alpha,beta-unsaturated monocarboxylic acid;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyanophenphos | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| difenoxin | | nitrile;
piperidinemonocarboxylic acid;
tertiary amine | antidiarrhoeal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| decamethrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organobromine compound | agrochemical;
antifeedant;
calcium channel agonist;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| closantel | | aromatic amide;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile;
organoiodine compound;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluvalinate | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide | agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bezitramide | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| d 888 | | aromatic ether;
nitrile;
tertiary amino compound | anti-arrhythmia drug;
calcium channel blocker;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyanopyrazine | | nitrile;
pyrazines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetracyanoquinodimethane | | alicyclic compound;
nitrile;
quinodimethane | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-chlorophenyl)-2-phenyl-2-(1,2,4-triazol-1-ylmethyl)butanenitrile | | monochlorobenzenes;
nitrile;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludioxonil | | benzodioxoles;
nitrile;
organofluorine compound;
pyrroles | androgen antagonist;
antifungal agrochemical;
estrogen receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenpiclonil | | dichlorobenzene;
nitrile;
pyrroles | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorfenapyr | | hemiaminal ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles | proacaricide;
proinsecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile | | dimethoxybenzene;
nitrile;
secondary amino compound | drug metabolite;
marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-bis(4-hydroxyphenyl)-propionitrile | | nitrile;
phenols | estrogen receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyfluthrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound | agrochemical;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norverapamil | | aromatic ether;
nitrile;
polyether;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| taxiphyllin | | beta-D-glucoside;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiacloprid | | monochloropyridine;
nitrile;
thiazolidines | environmental contaminant;
neonicotinoid insectide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| febuxostat | | 1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile | EC 1.17.3.2 (xanthine oxidase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-epithiobutanenitrile | | epithionitrile;
nitrile;
thiirane | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyc 682 | | nitrile;
nucleoside analogue;
secondary carboxamide | antimetabolite;
antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dhurrin | | beta-D-glucoside;
cyanogenic glycoside;
monosaccharide derivative;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminopotentidine | | aromatic ether;
benzamides;
guanidines;
nitrile;
piperidines;
substituted aniline | H2-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile | | monochlorobenzenes;
nitrile;
organobromine compound;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles | acaricide;
antifouling biocide;
insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-oxo-1-cyclohexenyl)amino]benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prizes | | carboxamidine;
monochloropyridine;
nitrile | environmental contaminant;
neonicotinoid insectide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 778,123 | | imidazoles;
monochlorobenzenes;
nitrile;
piperazinone;
tertiary amino compound | antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methyl-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| indole-3-acetonitrile | | indoles;
nitrile | auxin;
human xenobiotic metabolite;
plant hormone;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Girgensonine | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 214662 | | benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes | antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diclazuril | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mesoxalonitrile | | alpha-ketonitrile;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[di(propan-2-yl)phosphorylmethyl]benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| crotononitrile | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,6-diamino-4-(1-phenylethyl)-4H-thiopyran-3,5-dicarbonitrile | | nitrile;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-hydroxy-1-(3-hydroxypropyl)-4-methyl-2-oxo-5-(1-piperidinylmethyl)-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trilostane | | 17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile | abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-ethyl-4,6-dimethyl-2-sulfanylidene-1H-pyridine-3-carbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-3-(methoxymethyl)-5-spiro[2H-pyrano[2,3-c]pyrazole-4,4'-thiane]carbonitrile | | nitrile;
organic sulfide;
organosulfur heterocyclic compound;
oxaspiro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iFSP1 | | aromatic amine;
nitrile;
primary amino compound;
pyridobenzimidazole;
toluenes | antineoplastic agent;
ferroptosis inducer;
ferroptosis suppressor protein 1 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[(4-chloro-5-dithiazolylidene)amino]benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-amino-5-ethyl-4-(2-furanyl)-6-propyl-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone | | bromophenol;
nitrile;
pyridone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1H-imidazol-1-ylmethyl)benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-1-(4-chlorophenyl)-2-oxo-4-(1,2,4-triazol-1-ylmethyl)-5-pyrimidinecarbonitrile | | monochlorobenzenes;
nitrile;
pyrimidone;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-tert-butyl-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,6-dimethyl-2-[3-(4-morpholinyl)propylamino]-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(methylamino)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(1-piperidinyl)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-fluorophenyl)-2-[4-[(4-fluorophenyl)-oxomethyl]phenyl]acetonitrile | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-Chloro-2-hydroxy-4,6-dimethylnicotinonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-oxo-4,6-dithiophen-2-yl-1H-pyridine-3-carbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(4-chlorophenyl)methoxy]-6-methoxybenzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[[4-(2-furanylmethyl)-5-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]thio]methyl]benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| or 1259 | | hydrazone;
nitrile;
pyridazinone | anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azoxystrobin | | aryloxypyrimidine;
enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
methyl ester;
nitrile | antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
quinone outside inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fipronil sulfone | | (trifluoromethyl)benzenes;
dichlorobenzene;
nitrile;
pyrazoles;
sulfone | marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-[2-hydroxy-3-(4-morpholinyl)propoxy]phenyl]benzonitrile | | biphenyls;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nafadotride | | aromatic ether;
naphthalenecarboxamide;
nitrile;
pyrrolidines;
tertiary amino compound | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| entacapone | | 2-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyhalothrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound | agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[3-(diethylamino)propylamino]-4-(methoxymethyl)-6-methyl-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ag-490 | | catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide | anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-cyano-4-hydroxycinnamic acid | | monohydroxycinnamic acid;
nitrile;
phenols | MALDI matrix material | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bosutinib | | aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 11-7082 | | nitrile;
sulfone | apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 11-7085 | | benzenes;
nitrile;
sulfone | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
ferroptosis inducer;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| su 1498 | | enamide;
monocarboxylic acid amide;
nitrile;
phenols;
secondary carboxamide | vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tyrphostin ag825 | | aromatic ether;
benzothiazoles;
enamide;
nitrile;
organic sulfide;
phenols;
primary carboxamide | epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-(p-Methoxyphenyl)-2-pyridineacrylonitrile | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ekb 569 | | aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile | protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rilpivirine | | aminopyrimidine;
nitrile | EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vilazodone | | 1-benzofurans;
indoles;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
nitrile | antidepressant;
serotonergic agonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flonicamid | | nitrile;
organofluorine compound;
pyridinecarboxamide | environmental contaminant;
insecticide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyazofamid | | imidazole fungicide;
imidazoles;
nitrile;
organochlorine compound;
sulfamides;
sulfonamide fungicide | antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hki 272 | | nitrile;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perampanel | | bipyridines;
nitrile;
pyridone | AMPA receptor antagonist;
anticonvulsant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tofacitinib | | N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound | antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide | | 1,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 477118 | | adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alogliptin | | nitrile;
piperidines;
primary amino compound;
pyrimidines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyflumetofen | | (trifluoromethyl)benzenes;
2-methoxyethyl ester;
beta-ketoester;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| finafloxacin | | cyclopropanes;
monocarboxylic acid;
nitrile;
organofluorine compound;
quinolone;
secondary amino compound;
tertiary amino compound | antibacterial drug;
antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyantraniliprole | | nitrile;
organobromine compound;
organochlorine compound;
pyrazole insecticide;
pyridines;
secondary carboxamide | ryanodine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dactolisib | | imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha(-(cyclopropylcarbonyl)-2-(methyvlsulfonyl)-beta-oxo-4-(trifluromethyl)benzenepropanenitrile) | | (trifluoromethyl)benzenes;
aromatic ketone;
beta-diketone;
cyclopropanes;
nitrile;
sulfone | agrochemical;
EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mdv 3100 | | (trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound | androgen antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trelagliptin | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulfoxaflor | | nitrile;
organofluorine compound;
pyridines;
sulfoximide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyenopyrafen | | nitrile;
pivalate ester;
pyrazoles | agrochemical;
proacaricide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| SL-327 | | (trifluoromethyl)benzenes;
enamine;
nitrile;
organic sulfide;
primary amino compound;
substituted aniline | EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | | aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound | anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| incb-018424 | | nitrile;
pyrazoles;
pyrrolopyrimidine | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glasdegib | | benzimidazoles;
nitrile;
phenylureas;
piperidines | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| baricitinib | | azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide | anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monepantel | | (trifluoromethyl)benzenes;
aromatic ether;
aryl sulfide;
nitrile;
secondary carboxamide | anthelminthic drug;
nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| GS-441524 | | aromatic amine;
C-nucleoside;
nitrile;
pyrrolotriazine | anticoronaviral agent;
antiviral agent;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| an2728 | | aromatic ether;
benzoxaborole;
nitrile | antipsoriatic;
non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tak-632 | | (trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alectinib | | aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| delgocitinib | | azaspiro compound;
N-acylazetidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound;
tertiary carboxamide | anti-inflammatory drug;
antipsoriatic;
antiseborrheic;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lfm a13 | | aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| teriflunomide | | (trifluoromethyl)benzenes;
aromatic amide;
enamide;
enol;
nitrile;
secondary carboxamide | drug metabolite;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| GS-443902 | | aromatic amine;
C-nucleoside;
nitrile;
organic triphosphate;
pyrrolotriazine | anticoronaviral agent;
antiviral drug;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf-06463922 | | aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s 8932 | | aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine | anticoronaviral agent;
antiviral drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| AZ3451 | | benzimidazoles;
benzodioxoles;
nitrile;
organobromine compound;
secondary carboxamide | anti-inflammatory agent;
autophagy inducer;
PAR2 negative allosteric modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile | | hydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nirmatrelvir | | azabicyclohexane;
nitrile;
organofluorine compound;
pyrrolidin-2-ones;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide | anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fleroxacin | | difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines | antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluconazole | | conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug | environmental contaminant;
P450 inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,2-difluorobenzene | | difluorobenzene | anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| voriconazole | | conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| teflubenzuron | | dichlorobenzene;
difluorobenzene;
N-acylurea | environmental contaminant;
insecticide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flufenoxuron | | (trifluoromethyl)benzenes;
benzoylurea insecticide;
difluorobenzene;
monochlorobenzenes;
monofluorobenzenes | mite growth regulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vx-745 | | aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine | anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester | | carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester | EC 3.4.23.46 (memapsin 2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 0325901 | | difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound | antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly 411575 | | dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dafadine C | | aromatic amide;
aromatic ether;
difluorobenzene;
isoxazoles;
N-acylpiperidine;
pyridines | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pamapimod | | aromatic amine;
aromatic ether;
difluorobenzene;
diol;
primary alcohol;
pyridopyrimidine;
secondary amino compound | antirheumatic drug;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gdc-0973 | | aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plx 4720 | | aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide | antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| entrectinib | | benzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk 2126458 | | aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plx4032 | | aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide | antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk-5498a | | (trifluoromethyl)benzenes;
difluorobenzene;
pyrazoles;
secondary carboxamide | calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk1265744 | | difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide | HIV-1 integrase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dolutegravir | | difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide | HIV-1 integrase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| threo-alpha-methylisocitrate | | methylisocitric acid;
tertiary alcohol;
tricarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| meglutol | | 3-hydroxy carboxylic acid;
dicarboxylic acid;
tertiary alcohol | anticholesteremic drug;
antimetabolite;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
human metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biperiden | | piperidines;
tertiary alcohol;
tertiary amino compound | antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclopentolate | | carboxylic ester;
tertiary alcohol;
tertiary amino compound | diagnostic agent;
muscarinic antagonist;
mydriatic agent;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cycrimine | | piperidines;
tertiary alcohol;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenidol | | benzenes;
piperidines;
tertiary alcohol | antiemetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| heptaminol | | tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxybutynin | | acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound | antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pridinol | | piperidines;
tertiary alcohol | antiparkinson drug;
muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| procyclidine | | pyrrolidines;
tertiary alcohol | antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ultram | | aromatic ether;
tertiary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| venlafaxine | | cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound | adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorobutanol | | tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vincristine | | acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norethindrone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol | progestin;
synthetic oral contraceptive | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tert-butyl alcohol | | tertiary alcohol | human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tert-amyl alcohol | | aliphatic alcohol;
tertiary alcohol | protic solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| linalool | | monoterpenoid;
tertiary alcohol | antimicrobial agent;
fragrance;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxycitronellal | | tertiary alcohol | allergen;
fragrance | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxy-3-methylbutene | | olefinic compound;
tertiary alcohol | animal metabolite;
fragrance;
pheromone;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dicofol | | monochlorobenzenes;
organochlorine acaricide;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hematoxylin | | organic heterotetracyclic compound;
oxacycle;
polyphenol;
tertiary alcohol | histological dye;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol | | terpineol;
tertiary alcohol | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiparasitic agent;
apoptosis inducer;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-phenyl-2-propanol | | benzyl alcohols;
tertiary alcohol | human xenobiotic metabolite;
Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethylestrenol | | 17beta-hydroxy steroid;
tertiary alcohol | anabolic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tridihexethyl | | quaternary ammonium ion;
tertiary alcohol | anti-ulcer drug;
antispasmodic drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| camptothecin | | delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| stanozolol | | 17beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol | anabolic agent;
androgen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ancymidol | | pyrimidines;
tertiary alcohol | cellulose synthesis inhibitor;
gibberellin biosynthesis inhibitor;
plant growth retardant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butaclamol | | amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vindesine | | methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
primary carboxamide;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenarimol | | monochlorobenzenes;
pyrimidines;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cedrol | | cedrane sesquiterpenoid;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hexaconazole | | dichlorobenzene;
tertiary alcohol;
triazoles | chelator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| warburganal | | tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brazilin | | catechols;
organic heterotetracyclic compound;
tertiary alcohol | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
biological pigment;
hepatoprotective agent;
histological dye;
NF-kappaB inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tebuconazole | | monochlorobenzenes;
tertiary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyproconazole | | cyclopropanes;
monochlorobenzenes;
tertiary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metconazole | | conazole fungicide;
cyclopentanols;
monochlorobenzenes;
tertiary alcohol;
triazole fungicide;
triazoles | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (1-hydroxycyclopentyl)phenylacetic acid | | monocarboxylic acid;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beta-eudesmol | | carbobicyclic compound;
eudesmane sesquiterpenoid;
tertiary alcohol | volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flutriafol | | monofluorobenzenes;
tertiary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| elemol | | olefinic compound;
sesquiterpenoid;
tertiary alcohol | fragrance;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biperiden hydrochloride | | hydrochloride;
piperidines;
tertiary alcohol | antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spathulenol | | carbotricyclic compound;
olefinic compound;
sesquiterpenoid;
tertiary alcohol | anaesthetic;
plant metabolite;
vasodilator agent;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-eudesmol | | eudesmane sesquiterpenoid;
octahydronaphthalenes;
tertiary alcohol | volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sporidesmin | | aromatic ether;
cyclic ketone;
diketone;
organic disulfide;
organic heteropentacyclic compound;
organochlorine compound;
secondary alcohol;
tertiary alcohol;
tertiary amino compound | mycotoxin;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aeroplysinin i | | tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sn 38 | | delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol | antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paxilline | | diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol | anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cafestol | | diterpenoid;
furans;
organic heteropentacyclic compound;
primary alcohol;
tertiary alcohol | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kahweol | | diterpenoid;
furans;
organic heteropentacyclic compound;
primary alcohol;
tertiary alcohol | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| megestrol acetate | | bridged compound;
organic heterotetracyclic compound;
secondary alcohol;
sesquiterpene lactone;
spiro compound;
tertiary alcohol;
tetrol | GABA antagonist;
neurotoxin;
phytogenic insecticide;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aclacinomycin | | aminoglycoside;
anthracycline;
deoxy hexoside;
methyl ester;
monosaccharide derivative;
phenols;
polyketide;
tertiary alcohol;
tetracenequinones;
zwitterion | antimicrobial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| columbianetin | | furanocoumarin;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aklavinone | | anthracycline;
methyl ester;
tertiary alcohol;
tetracenequinones | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| t-cadinol | | cadinane sesquiterpenoid;
carbobicyclic compound;
octahydronaphthalenes;
tertiary alcohol | plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| withanolide d | | 20-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
secondary alcohol;
tertiary alcohol;
withanolide | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diplopterol | | hopanoid;
pentacyclic triterpenoid;
tertiary alcohol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| inuviscolide | | gamma-lactone;
organic heterotricyclic compound;
sesquiterpene lactone;
tertiary alcohol | anti-inflammatory agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diflomotecan | | epsilon-lactone;
organic heteropentacyclic compound;
organofluorine compound;
organonitrogen heterocyclic compound;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vincaleukoblastine | | acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Ovalicine subst. | | tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| homoharringtonine | | alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deltaline | | acetate ester;
cyclic acetal;
diterpene alkaloid;
organic polycyclic compound;
tertiary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phorbol | | cyclic ketone;
enone;
tertiary alcohol;
tertiary alpha-hydroxy ketone;
tetracyclic diterpenoid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picrotin | | diol;
epoxide;
gamma-lactone;
organic heteropentacyclic compound;
picrotoxane sesquiterpenoid;
tertiary alcohol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picrotoxinin | | epoxide;
gamma-lactone;
organic heteropentacyclic compound;
picrotoxane sesquiterpenoid;
tertiary alcohol | GABA antagonist;
plant metabolite;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cinnamodial | | tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| theogallin | | gallate ester;
monocarboxylic acid;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kt 5720 | | carboxylic ester;
gamma-lactam;
hemiaminal;
indolocarbazole;
organic heterooctacyclic compound;
semisynthetic derivative;
tertiary alcohol | EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 16beta,17-dihydroxy-ent-kaurane-19-oic acid | | bridged compound;
diol;
ent-kaurane diterpenoid;
hydroxy monocarboxylic acid;
primary alcohol;
tertiary alcohol | anti-HIV agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubitecan | | C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| efinaconazole | | conazole antifungal drug;
olefinic compound;
organofluorine compound;
piperidines;
tertiary alcohol;
tertiary amino compound;
triazole antifungal drug | EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| manool | | labdane diterpenoid;
tertiary alcohol | antibacterial agent;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| t-muurolol | | cadinane sesquiterpenoid;
carbobicyclic compound;
octahydronaphthalenes;
tertiary alcohol | bacterial metabolite;
fungicide;
marine metabolite;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| blister | | cyclic ketone;
pyrroloquinoline;
tertiary alcohol;
tertiary alpha-hydroxy ketone | inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| senecionine | | lactone;
pyrrolizidine alkaloid;
tertiary alcohol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azadirachtin | | acetate ester;
azadirachtin;
cyclic hemiketal;
enoate ester;
epoxide;
methyl ester;
organic heterotetracyclic compound;
secondary alcohol;
tertiary alcohol | hepatoprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ophiobolin a | | cyclic ketone;
enal;
oxaspiro compound;
sesterterpenoid;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| josamycin | | acetate ester;
aldehyde;
disaccharide derivative;
glycoside;
macrolide antibiotic;
tertiary alcohol;
tertiary amino compound | antibacterial drug;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethisterone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol | drug metabolite;
progestin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naloxone | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol | antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lasalocid | | beta-hydroxy ketone;
monocarboxylic acid;
monohydroxybenzoic acid;
oxanes;
oxolanes;
polyether antibiotic;
secondary alcohol;
tertiary alcohol | bacterial metabolite;
coccidiostat;
ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rhodopin | | carotenol;
tertiary alcohol | bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bedaquiline | | aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound | antitubercular agent;
ATP synthase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| manumycin | | enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol | antiatherosclerotic agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| squalestatin 1 | | acetate ester;
cyclic ketal;
oxabicycloalkane;
polyketide;
tertiary alcohol;
tricarboxylic acid | EC 2.5.1.21 (squalene synthase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| riddelliine n-oxide | | diol;
macrocyclic lactone;
olefinic compound;
organic heterotricyclic compound;
primary alcohol;
pyrrolizine alkaloid;
tertiary alcohol;
tertiary amine oxide | carcinogenic agent;
genotoxin;
human xenobiotic metabolite;
Jacobaea metabolite;
mutagen;
rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asukamycin | | enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bacterioruberin | | C50 carotenoid;
tertiary alcohol;
tetrol | bacterial metabolite;
biological pigment | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prothioconazole | | cyclopropanes;
monochlorobenzenes;
tertiary alcohol;
thiocarbonyl compound;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yunaconitine | | acetate ester;
aromatic ether;
benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound | antifeedant;
human urinary metabolite;
phytotoxin;
plant metabolite;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| grayanotoxin i | | acetate ester;
pentol;
secondary alcohol;
tertiary alcohol;
tetracyclic diterpenoid | antihypertensive agent;
metabolite;
neuromuscular agent;
phytotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-demethylloperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tmc-95a | | indoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol | antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
fungal metabolite;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yw 3548 | | olefinic compound;
terpene lactone;
tertiary alcohol | fungal metabolite;
glycerophosphoinositol synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| arisugacin | | aromatic ether;
delta-lactone;
enone;
organic heterotetracyclic compound;
tertiary alcohol | antimicrobial agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-cadinol | | cadinane sesquiterpenoid;
carbobicyclic compound;
octahydronaphthalenes;
tertiary alcohol | fungicide;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxyibuprofen | | hydroxy monocarboxylic acid;
tertiary alcohol | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tmc-95b | | indoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol | antimicrobial agent;
antineoplastic agent;
fungal metabolite;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| homocamptothecin | | epsilon-lactone;
organic heteropentacyclic compound;
organonitrogen heterocyclic compound;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ossamycin | | cyclic hemiketal;
macrolide antibiotic;
organic heterotetracyclic compound;
secondary alcohol;
spiroketal;
tertiary alcohol | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vibrioferrin | | carboxylic ester;
N-acyl hemiaminal;
pyrrolidin-2-ones;
tertiary alcohol;
tricarboxylic acid | marine metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cubebol | | carbotricyclic compound;
sesquiterpenoid;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| myrocin a | | tertiary alcohol | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diversonol | | phenols;
tertiary alcohol | antibacterial agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zaragozic acid c | | acetate ester;
cyclic ketal;
oxabicycloalkane;
polyketide;
tertiary alcohol;
tricarboxylic acid | EC 2.5.1.21 (squalene synthase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| viridiflorol | | carbotricyclic compound;
sesquiterpenoid;
tertiary alcohol | anti-inflammatory agent;
antifeedant;
antimycobacterial drug;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oplodiol | | carbobicyclic compound;
octahydronaphthalenes;
secondary alcohol;
sesquiterpenoid;
tertiary alcohol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kt 5926 | | gamma-lactam;
hemiaminal;
indolocarbazole;
methyl ester;
organic heterooctacyclic compound;
tertiary alcohol | EC 2.7.11.18 (myosin-light-chain kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methampicillin | | monochlorobenzenes;
tertiary alcohol;
triazoles | brassinosteroid biosynthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aflatoxin m1 | | aflatoxin;
aromatic ether;
aromatic ketone;
tertiary alcohol | Aspergillus metabolite;
human xenobiotic metabolite;
mammalian metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vibsanin b | | cyclic terpene ketone;
enone;
tertiary alcohol;
vibsane diterpenoid | plant growth retardant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| germacradienol | | germacrane sesquiterpenoid;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk690693 | | 1,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 7545 | | benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide | EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzoylaconine | | benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound;
tetrol | phytotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| berkeleydione | | beta-diketone;
cyclic terpene ketone;
meroterpenoid;
methyl ester;
organic heterotetracyclic compound;
terpene lactone;
tertiary alcohol;
tertiary alpha-hydroxy ketone | antineoplastic agent;
cysteine protease inhibitor;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| berkeleytrione | | beta-diketone;
carbopolycyclic compound;
cyclic terpene ketone;
meroterpenoid;
methyl ester;
tertiary alcohol;
tertiary alpha-hydroxy ketone | cysteine protease inhibitor;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromophycolide a | | diterpenoid;
macrolide;
organobromine compound;
phenols;
tertiary alcohol | anti-HIV agent;
antibacterial agent;
antifungal agent;
antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| caribenol a | | organic heterotetracyclic compound;
terpene lactone;
tertiary alcohol | antimalarial;
antitubercular agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzoylmesaconine | | benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound;
tetrol | analgesic;
antiinfective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| papuamide b | | cyclodepsipeptide;
olefinic compound;
secondary alcohol;
tertiary alcohol | anti-HIV-1 agent;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| staphyloferrin b | | oxo carboxylic acid;
tertiary alcohol;
tricarboxylic acid amide;
tricarboxylic acid | bacterial metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| staphyloferrin a | | D-ornithine derivative;
pentacarboxylic acid;
tertiary alcohol;
tricarboxylic acid amide | bacterial metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eurycomanone | | cyclic ether;
delta-lactone;
enone;
organic heteropentacyclic compound;
pentol;
quassinoid;
secondary alcohol;
secondary alpha-hydroxy ketone;
tertiary alcohol | antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gardenoside | | beta-D-glucoside;
cyclopentapyran;
enoate ester;
methyl ester;
monosaccharide derivative;
tertiary alcohol | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asperfuranone | | 2-benzofurans;
cyclic ketone;
diol;
polyketide;
secondary alcohol;
tertiary alcohol;
tertiary alpha-hydroxy ketone | antineoplastic agent;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naloxegol | | aromatic ether;
organic heteropentacyclic compound;
phenols;
polyether;
tertiary alcohol | cathartic;
mu-opioid receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
tertiary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| praliciguat | | aminopyrimidine;
isoxazoles;
monofluorobenzenes;
organofluorine compound;
pyrazoles;
secondary amino compound;
tertiary alcohol | anti-inflammatory agent;
antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ambrein | | tertiary alcohol;
triterpenoid | hypoglycemic agent;
mammalian metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enasidenib | | 1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aurachin a | | A-type aurachin;
furoquinoline;
quinoline N-oxide;
tertiary alcohol | antibacterial agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclooctatin | | carbotricyclic compound;
diterpenoid;
primary alcohol;
secondary alcohol;
tertiary alcohol | bacterial metabolite;
EC 3.1.1.5 (lysophospholipase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| grayanotoxin ii | | tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| itraconazole | | aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles | EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fosfluconazole | | conazole antifungal drug;
triazole antifungal drug;
triazoles | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clotrimazole | | conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | antiinfective agent;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| croconazole | | aromatic ether;
conazole antifungal drug;
imidazole antifungal drug;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butoconazole nitrate | | aryl sulfide;
conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
organic nitrate salt | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butoconazole | | aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulconazole, mononitrate, (+-)-isomer | | conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| latoconazole | | conazole antifungal drug;
imidazole antifungal drug | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neticonazole | | aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide | antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxiconazole | | conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether | antiinfective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sgd 301-76 | | conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt | antiinfective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| b 844-39 | | diarylmethane | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| benzbromarone | | 1-benzofurans;
aromatic ketone | uricosuric drug | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| candesartan cilexetil | | biphenyls | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| clofazimine | | monochlorobenzenes;
phenazines | dye;
leprostatic drug;
non-steroidal anti-inflammatory drug | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dipyridamole | | piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol | adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fluconazole | | conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug | environmental contaminant;
P450 inhibitor;
xenobiotic | 2007 | 2022 | 13.4 | low | 0 | 0 | 0 | 6 | 0 | 1 |
| flucytosine | | aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone | prodrug | 2007 | 2009 | 16.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| furosemide | | chlorobenzoic acid;
furans;
sulfonamide | environmental contaminant;
loop diuretic;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| itraconazole | | piperazines | | 2007 | 2022 | 9.0 | low | 0 | 0 | 0 | 3 | 0 | 3 |
| lansoprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nicardipine | | benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nimodipine | | 2-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester | antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nitrendipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester | antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| omeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pantoprazole | | aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rabeprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| imatinib | | aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines | antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sulfasalazine | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| delavirdine | | aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| reserpine | | alkaloid ester;
methyl ester;
yohimban alkaloid | adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 1,3-benzodioxole | | benzodioxole | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mefloquine | | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| efavirenz | | acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nelfinavir | | aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound | antineoplastic agent;
HIV protease inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amprenavir | | carbamate ester;
sulfonamide;
tetrahydrofuryl ester | antiviral drug;
HIV protease inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| telmisartan | | benzimidazoles;
biphenyls;
carboxybiphenyl | angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| voriconazole | | conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug | P450 inhibitor | 2007 | 2021 | 13.8 | low | 0 | 0 | 0 | 7 | 0 | 1 |
| atovaquone | | hydroxy-1,2-naphthoquinone | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| lopinavir | | amphetamines;
dicarboxylic acid diamide | anticoronaviral agent;
antiviral drug;
HIV protease inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| febuxostat | | 1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile | EC 1.17.3.2 (xanthine oxidase) inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| atazanavir | | carbohydrazide | antiviral drug;
HIV protease inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| anidulafungin | | antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erlotinib | | aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound | antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tryptoquivaline | | aromatic ether;
indole alkaloid;
organic heteropentacyclic compound | breast cancer resistance protein inhibitor;
mycotoxin | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| saquinavir | | L-asparagine derivative;
quinolines | antiviral drug;
HIV protease inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| abacavir | | 2,6-diaminopurines | antiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 6-prenylchrysin | | 7-hydroxyflavonol;
dihydroxyflavone | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| tacrolimus | | macrolide lactam | bacterial metabolite;
immunosuppressive agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ketoconazole | | cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| ravuconazole | | 1,3-thiazoles;
fluorobenzenes;
nitrile;
tertiary alcohol;
triazoles | antifungal drug;
antileishmanial agent;
EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 2008 | 2022 | 11.3 | low | 0 | 0 | 0 | 5 | 0 | 2 |
| micafungin | | antibiotic antifungal drug;
echinocandin | antiinfective agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| efinaconazole | | conazole antifungal drug;
olefinic compound;
organofluorine compound;
piperidines;
tertiary alcohol;
tertiary amino compound;
triazole antifungal drug | EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| s 1033 | | (trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| chlorprothixene | | chlorprothixene | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| curcumin | | aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cancidas | | | | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| fusidic acid | | 11alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester | EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tak 456 | | | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 2-(2,4-difluorophenyl)-3-(4-(4-(2-(4-trifluoromethoxybenzyl)-2h-1,2,4-triazol-3-one-4-yl)phenyl)piperazin-1-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol | | | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| zd 6474 | | aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine | antineoplastic agent;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sq 109 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| apigenin | | trihydroxyflavone | antineoplastic agent;
metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amphotericin b | | antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic | antiamoebic agent;
antiprotozoal drug;
bacterial metabolite | 2007 | 2022 | 12.8 | low | 0 | 0 | 0 | 4 | 0 | 1 |
| l 660,711 | | quinolines | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tectochrysin | | monohydroxyflavone;
monomethoxyflavone | antidiarrhoeal drug;
antineoplastic agent;
plant metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cyclosporine | | homodetic cyclic peptide | anti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| topiroxostat | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bosutinib | | aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 3,3',4,5'-tetramethoxy-trans-stilbene | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| proguanil | | biguanides;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rilpivirine | | aminopyrimidine;
nitrile | EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| r-120758 | | | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| timcodar | | | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| tivozanib | | aromatic ether | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ko 143 | | beta-carbolines;
tert-butyl ester | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| regorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide | antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fostamatinib | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gdc 0449 | | benzamides;
monochlorobenzenes;
pyridines;
sulfone | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ponatinib | | (trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine | antineoplastic agent;
tyrosine kinase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cobicistat | | 1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas | P450 inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| alectinib | | aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| novobiocin | | carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols | antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| chir 258 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amg531 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:9, 2010
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:4, 2010
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:1, 2009
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:5, 2007
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:1, 2009
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:5, 2007
Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.Journal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:4, 2010
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:5, 2007
Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.Journal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:9, 2010
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:4, 2010
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:4, 2009
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:1, 2009
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:5, 2007
Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.Journal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:9, 2010
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:4, 2010
In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:4, 2009
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:1, 2009
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:4, 2010
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:1, 2009
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:5, 2007
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| carbamates | | amino-acid anion | | 2016 | 2017 | 7.7 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| bupropion | | aromatic ketone;
monochlorobenzenes;
secondary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| 1-octanol | | octanol;
primary alcohol | antifungal agent;
bacterial metabolite;
fuel additive;
kairomone;
plant metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clotrimazole | | conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | antiinfective agent;
environmental contaminant;
xenobiotic | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluconazole | | conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug | environmental contaminant;
P450 inhibitor;
xenobiotic | 2008 | 2023 | 8.6 | low | 1 | 0 | 0 | 6 | 17 | 4 |
| flucytosine | | aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone | prodrug | 2010 | 2018 | 10.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| hydroxychloroquine | | aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ibuprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ketoconazole | | dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine | | 2012 | 2023 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| methadone | | benzenes;
diarylmethane;
ketone;
tertiary amino compound | | 2017 | 2019 | 6.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| miconazole | | dichlorobenzene;
ether;
imidazoles | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| potassium iodide | | potassium salt | expectorant;
radical scavenger | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| galactose | | D-galactose;
galactopyranose | Escherichia coli metabolite;
mouse metabolite | 2016 | 2020 | 6.9 | low | 2 | 0 | 0 | 0 | 8 | 0 |
| carbostyril | | monohydroxyquinoline;
quinolone | bacterial xenobiotic metabolite | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| acetonitrile | | aliphatic nitrile;
volatile organic compound | EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrroles | | pyrrole;
secondary amine | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiophenes | | mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound | non-polar solvent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quinazolines | | azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines | | 2010 | 2011 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2010 | 2020 | 10.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| alpha-aminopyridine | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vancomycin | | glycopeptide | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| floxacillin | | penicillin allergen;
penicillin | antibacterial drug | 2021 | 2022 | 2.5 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| deuterium | | dihydrogen | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azides | | pseudohalide anion | mitochondrial respiratory-chain inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| itraconazole | | aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles | EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor | 2006 | 2023 | 6.5 | low | 0 | 0 | 0 | 2 | 23 | 10 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| repaglinide | | piperidines | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| triazoles | | 1,2,3-triazole | | 2006 | 2023 | 6.3 | high | 37 | 0 | 0 | 27 | 232 | 80 |
| voriconazole | | conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug | P450 inhibitor | 2006 | 2023 | 6.1 | medium | 7 | 0 | 0 | 7 | 56 | 26 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| moxifloxacin | | aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| anidulafungin | | antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative | | 2010 | 2021 | 6.9 | low | 0 | 0 | 0 | 1 | 8 | 1 |
| albaconazole | | | | 2010 | 2011 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| deoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human blood serum metabolite | 2014 | 2021 | 6.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| epiglucan | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| laminaran | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| griseofulvin | | 1-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound | antibacterial agent;
Penicillium metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ergosterol | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols | fungal metabolite;
Saccharomyces cerevisiae metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tacrolimus | | macrolide lactam | bacterial metabolite;
immunosuppressive agent | 2017 | 2023 | 3.6 | low | 1 | 0 | 0 | 0 | 5 | 5 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 2017 | 2021 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| zithromax | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
xenobiotic | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ravuconazole | | 1,3-thiazoles;
fluorobenzenes;
nitrile;
tertiary alcohol;
triazoles | antifungal drug;
antileishmanial agent;
EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor | 2010 | 2022 | 9.0 | low | 0 | 0 | 0 | 2 | 3 | 1 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 2009 | 2023 | 6.8 | medium | 0 | 0 | 0 | 4 | 47 | 9 |
| l 743,872 | | | | 2006 | 2023 | 7.8 | low | 1 | 0 | 0 | 2 | 15 | 3 |
| micafungin | | antibiotic antifungal drug;
echinocandin | antiinfective agent | 2012 | 2018 | 8.8 | low | 0 | 0 | 0 | 0 | 13 | 0 |
| dipyrone | | organic sodium salt | anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glycosides | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terbinafine | | acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor | 2012 | 2023 | 6.8 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| digoxin | | cardenolide glycoside;
steroid saponin | anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| galactomannan | | oligosaccharide | | 2016 | 2020 | 6.9 | low | 2 | 0 | 0 | 0 | 8 | 0 |
| amphotericin b | | antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic | antiamoebic agent;
antiprotozoal drug;
bacterial metabolite | 2009 | 2023 | 6.6 | low | 0 | 0 | 0 | 4 | 37 | 13 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2017 | 2019 | 5.7 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| dextromethorphan | | 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene | antitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| flibanserin | | benzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound | antidepressant;
serotonergic agonist;
serotonergic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| staurosporine | | ammonium ion derivative | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lenvatinib | | aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| midostaurin | | benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound | antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nystatin a1 | | nystatins | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aminocandin | | aromatic ether;
echinocandin;
homodetic cyclic peptide | antiinfective agent | 2010 | 2011 | 13.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| brexpiprazole | | N-arylpiperazine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vx-770 | | aromatic amide;
monocarboxylic acid amide;
phenols;
quinolone | CFTR potentiator;
orphan drug | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lumacaftor | | aromatic amide;
benzodioxoles;
benzoic acids;
cyclopropanes;
organofluorine compound;
pyridines | CFTR potentiator;
orphan drug | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amphotericin b, deoxycholate drug combination | | | | 2014 | 2021 | 6.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| ro13-9904 | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pci 32765 | | acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mannans | | | | 2016 | 2020 | 6.9 | low | 2 | 0 | 0 | 0 | 8 | 0 |
| bms-790052 | | biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative | antiviral drug;
nonstructural protein 5A inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| piperidines | | | | 2017 | 2020 | 5.3 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| interleukin-8 | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| colistin | | | | 2020 | 2022 | 3.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| mk-3118 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mobic | | 1,3-thiazoles;
benzothiazine;
monocarboxylic acid amide | analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| warfarin | | benzenes;
hydroxycoumarin;
methyl ketone | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| agar | | | | 2018 | 2020 | 5.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| daptomycin | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclosporine | | | | 2017 | 2022 | 4.7 | low | 1 | 0 | 0 | 0 | 2 | 1 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| 2019 Novel Coronavirus Disease | 0 | | 2020 | 2023 | 2.2 | low | 0 | 0 | 0 | 0 | 1 | 7 |
| Abscess | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Abscess, Amebic | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acanthamoeba Keratitis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acanthamoeba Meningoencephalitis | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Actinomycetoma | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Disease | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Hepatic Failure | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Hypercapnic Respiratory Failure | 0 | | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Acute Kidney Failure | 0 | | 2021 | 2022 | 2.5 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Acute Kidney Injury | 0 | | 2021 | 2022 | 2.5 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Acute Liver Injury, Drug-Induced | 0 | | 2018 | 2022 | 4.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Acute Lymphoid Leukemia | 0 | | 2018 | 2020 | 5.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Acute Myelogenous Leukemia | 0 | | 2014 | 2023 | 5.0 | low | 2 | 0 | 0 | 0 | 8 | 3 |
| Acute Respiratory Distress Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adverse Drug Event | 0 | | 2006 | 2023 | 5.9 | low | 2 | 0 | 0 | 1 | 9 | 2 |
| Agnogenic Myeloid Metaplasia | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Allergic Bronchopulmonary Aspergilloses | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Allergic Bronchopulmonary Mycosis | 0 | | 2012 | 2022 | 6.8 | low | 3 | 0 | 0 | 0 | 16 | 2 |
| Allergy, Drug | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Amebiasis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia, Aplastic | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia, Hypoplastic | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Angioedema | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Angioneurotic Edema | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Arrhythmia | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Arrhythmias, Cardiac | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Aspergilloses, Bronchopulmonary | 0 | | 2017 | 2023 | 4.1 | low | 1 | 0 | 0 | 0 | 7 | 3 |
| Aspergillosis | 1 | | 2006 | 2023 | 6.0 | low | 13 | 0 | 0 | 2 | 50 | 19 |
| Aspergillosis, Allergic Bronchopulmonary | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aspergillosis, Nervous System Invasive | 0 | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Aspergillus Infection | 0 | | 2006 | 2023 | 6.0 | low | 13 | 0 | 0 | 2 | 50 | 19 |
| Atrial Fibrillation | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Auricular Fibrillation | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Autosomal Recessive Chronic Granulomatous Disease | 0 | | 2017 | 2019 | 5.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| B-Cell Chronic Lymphocytic Leukemia | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| B-Cell Leukemia | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Benign Neoplasms | 0 | | 2018 | 2023 | 2.5 | low | 0 | 0 | 0 | 0 | 1 | 3 |
| Bilateral Headache | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Biliary Cirrhosis | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Blastomyces brasiliensis Infection | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Blastomycosis | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Blastomycosis, North American | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Bleeding | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Blood Diseases | 0 | | 2018 | 2023 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Brain Abscess | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Brain Diseases | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Brain Disorders | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Breast Cancer | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Breast Neoplasms | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Bronchopulmonary Sequestration | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bronze Diabetes | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Burns | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| C gattii Infection | 0 | | 2008 | 2023 | 7.0 | low | 2 | 0 | 0 | 1 | 3 | 2 |
| Cancer of Lung | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Candida Infection | 0 | | 2006 | 2020 | 9.9 | low | 1 | 0 | 0 | 3 | 10 | 0 |
| Candidemia | 1 | | 2015 | 2019 | 6.6 | low | 1 | 0 | 0 | 0 | 7 | 0 |
| Candidiasis | 0 | | 2006 | 2020 | 9.9 | low | 1 | 0 | 0 | 3 | 10 | 0 |
| Candidiasis, Genital | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Candidiasis, Invasive | 0 | | 2011 | 2022 | 6.8 | low | 1 | 0 | 0 | 0 | 9 | 4 |
| Candidiasis, Oral | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Candidiasis, Vulvovaginal | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cannabis Abuse | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cat Diseases | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Central Nervous System Disease | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Central Nervous System Diseases | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Central Nervous System Fungal Infections | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Central Nervous System Phaeohyphomycosis | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cerebral Cryptococcosis | 0 | | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cerebromeningitis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 2018 | 2022 | 4.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Chromoblastomycosis | 0 | | 2010 | 2020 | 9.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Chronic Disease | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Illness | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Kidney Failure | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Cirrhosis, Liver | 0 | | 2017 | 2018 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Co-infection | 0 | | 2018 | 2021 | 4.5 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| Cocaine Abuse | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cocaine-Related Disorders | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Coccidioides immitis Infection | 0 | | 2015 | 2023 | 5.2 | low | 1 | 0 | 0 | 0 | 3 | 2 |
| Coccidioidomycosis | 0 | | 2015 | 2023 | 5.2 | low | 1 | 0 | 0 | 0 | 3 | 2 |
| Communicable Diseases, Emerging | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Congenital Zika Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Corneal Ulcer | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Coronavirus Infections | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Critical Illness | 0 | | 2017 | 2023 | 2.9 | low | 0 | 0 | 0 | 0 | 2 | 5 |
| Cryptococcosis | 0 | | 2008 | 2023 | 7.0 | low | 2 | 0 | 0 | 1 | 3 | 2 |
| Cutaneous Phaeohyphomycosis | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Cystic Fibrosis | 0 | | 2017 | 2021 | 5.4 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| Cystic Fibrosis of Pancreas | 0 | | 2017 | 2021 | 5.4 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| Cytomegalic Inclusion Disease | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cytomegalovirus | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cytomegalovirus Infections | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Dermatomycoses | 0 | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Dermatophytoses | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetes Mellitus, Adult-Onset | 0 | | 2020 | 2022 | 3.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Diabetes Mellitus, Type 2 | 0 | | 2020 | 2022 | 3.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Disease Exacerbation | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Disease Models, Animal | 0 | | 2006 | 2021 | 8.5 | low | 1 | 0 | 0 | 3 | 9 | 1 |
| Disease, Pulmonary | 0 | | 2020 | 2021 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Disseminated Fungal Infection | 0 | | 2016 | 2023 | 4.4 | medium | 11 | 0 | 0 | 0 | 45 | 22 |
| Disseminated Fusariosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drug Abuse, Intravenous | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drug Hypersensitivity | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drug-Related Side Effects and Adverse Reactions | 0 | | 2006 | 2023 | 5.9 | low | 2 | 0 | 0 | 1 | 9 | 2 |
| Dysmyelopoietic Syndromes | 0 | | 2018 | 2021 | 4.5 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| Electrocardiogram QT Prolonged | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Encephalitis Infection | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Endotoxin Shock | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Entomophthoramycosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Esophageal Diseases | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Experimental Lung Inflammation | 0 | | 2015 | 2021 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Eye Infections, Fungal | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Fungal Diseases | 0 | | 2008 | 2023 | 7.6 | low | 5 | 0 | 0 | 8 | 26 | 8 |
| Fungal Lung Diseases | 0 | | 2014 | 2020 | 6.9 | low | 0 | 0 | 0 | 0 | 7 | 0 |
| Fungal Meningitis | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Fungemia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fusariosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Graft vs Host Disease | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Graft-Versus-Host Disease | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Granulocytic Leukemia | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Granuloma, Hodgkin | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Granulomatous Disease, Chronic | 0 | | 2017 | 2019 | 5.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Grippe | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Headache | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hematologic Diseases | 0 | | 2018 | 2023 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Hematologic Malignancies | 0 | | 2019 | 2023 | 3.2 | low | 0 | 0 | 0 | 0 | 4 | 2 |
| Hematologic Neoplasms | 0 | | 2019 | 2023 | 3.2 | low | 0 | 0 | 0 | 0 | 4 | 2 |
| Hemochromatosis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hemorrhage | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hepatic Veno Occlusive Disease | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hepatic Veno-Occlusive Disease | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Histoplasma capsulatum Infection | 0 | | 2016 | 2023 | 5.0 | low | 1 | 0 | 0 | 0 | 2 | 1 |
| Histoplasmosis | 0 | | 2016 | 2023 | 5.0 | low | 1 | 0 | 0 | 0 | 2 | 1 |
| Hodgkin Disease | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperoxaluria, Primary | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Infections, Coronavirus | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Paramyxoviridae | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Respiratory | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Infections, Staphylococcal | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Influenza, Human | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infusion Site Adverse Event | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Keratitis, Acanthamoeba | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Keratitis, Ulcerative | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Kidney Failure | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Kidney Failure, Chronic | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Lassa Fever | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lassa Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leucocythaemia | 0 | | 2018 | 2023 | 4.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Leukemia | 0 | | 2018 | 2023 | 4.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Leukemia, Lymphoblastic, Acute, T Cell | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Leukemia, Myeloid | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leukemia, Myeloid, Acute | 1 | | 2014 | 2023 | 5.0 | low | 2 | 0 | 0 | 0 | 8 | 3 |
| Liver Cirrhosis | 0 | | 2017 | 2018 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Liver Cirrhosis, Biliary | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Liver Diseases | 0 | | 2009 | 2018 | 9.7 | low | 2 | 0 | 0 | 1 | 2 | 0 |
| Liver Dysfunction | 0 | | 2009 | 2018 | 9.7 | low | 2 | 0 | 0 | 1 | 2 | 0 |
| Liver Failure, Acute | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Long QT Syndrome | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lung Diseases | 0 | | 2020 | 2021 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Lung Neoplasms | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Marijuana Abuse | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Meningitis, Cryptococcal | 0 | | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Moniliasis, Oral | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Mucorales Infection | 0 | | 2014 | 2023 | 5.7 | low | 5 | 0 | 0 | 0 | 45 | 17 |
| Mucormycosis | 0 | | 2014 | 2023 | 5.7 | low | 5 | 0 | 0 | 0 | 45 | 17 |
| Mucositis | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Mycetoma | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Mycoses | 1 | | 2008 | 2023 | 7.6 | low | 5 | 0 | 0 | 8 | 26 | 8 |
| Myelodysplastic Syndromes | 0 | | 2018 | 2021 | 4.5 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| Nail Fungus | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Necrosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neoplasms | 0 | | 2018 | 2023 | 2.5 | low | 0 | 0 | 0 | 0 | 1 | 3 |
| Neuroaspergillosis | 0 | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Neutropenia | 0 | | 2006 | 2018 | 10.8 | low | 2 | 0 | 0 | 2 | 3 | 0 |
| Obesity | 0 | | 2016 | 2022 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Onychomycosis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Opportunistic Infections | 0 | | 2008 | 2019 | 9.6 | low | 0 | 0 | 0 | 2 | 6 | 0 |
| Orphan Diseases | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Osteomyelitis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Oxaluria, Primary | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Paramyxoviridae Infections | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pneumonia | 0 | | 2015 | 2021 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Pneumonia, Viral | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 0 | | 2018 | 2020 | 5.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pregnancy | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Primary Myelofibrosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulmonary Aspergillosis | 0 | | 2017 | 2023 | 4.1 | low | 1 | 0 | 0 | 0 | 7 | 3 |
| Recrudescence | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Renal Insufficiency | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Respiratory Distress Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Respiratory Insufficiency | 0 | | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Respiratory Tract Infections | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Sensitivity and Specificity | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Shock, Septic | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sinus Infections | 0 | | 2021 | 2021 | 3.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Sinusitis | 0 | | 2021 | 2021 | 3.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Sporothrix brasiliensis Infection | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Sporotrichosis | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Staphylococcal Infections | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Tinea | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Zika Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Zygomycosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.Scientific reports, , 04-25, Volume: 13, Issue:1, 2023
Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study.Therapeutic drug monitoring, , 04-01, Volume: 45, Issue:2, 2023
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.Mycoses, , Volume: 66, Issue:5, 2023
Study of an antifungal medicine isavuconazole used in treatment of mold infections in China: A plain language summary.Future microbiology, , Volume: 18, 2023
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.Transplantation, , 03-01, Volume: 107, Issue:3, 2023
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study.Medical mycology, , Apr-03, Volume: 61, Issue:4, 2023
Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.Future microbiology, , Volume: 17, 2022
Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , 07-22, Volume: 79, Issue:15, 2022
Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).Microbiology spectrum, , 02-23, Volume: 10, Issue:1, 2022
Efficacy and safety of Isavuconazole for the treatment of invasive Expert opinion on pharmacotherapy, , Volume: 23, Issue:5, 2022
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.Mycoses, , Volume: 65, Issue:2, 2022
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada.Expert review of pharmacoeconomics & outcomes research, , Volume: 22, Issue:5, 2022
Broad-spectrum azoles and flucloxacillin: a dangerous match.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, , Volume: 41, Issue:1, 2022
Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 09-15, Volume: 73, Issue:6, 2021
The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.Mycoses, , Volume: 64, Issue:1, 2021
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.Mycoses, , Volume: 64, Issue:4, 2021
Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.Mycoses, , Volume: 63, Issue:1, 2020
Ibrutinib related cerebral aspergillosis successfully treated with isavuconazole: a case report.Leukemia & lymphoma, , Volume: 61, Issue:7, 2020
Intravenous isavuconazole can be administered 5 days-a-week. A possibility suggested by a real-life observation.Journal of chemotherapy (Florence, Italy), , Volume: 32, Issue:4, 2020
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.Diagnostic microbiology and infectious disease, , Volume: 97, Issue:1, 2020
Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient.Mycopathologia, , Volume: 185, Issue:2, 2020
Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation.Chemotherapy, , Volume: 64, Issue:2, 2019
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 74, Issue:3, 2019
Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:11, 2019
Isavuconazole Diffusion in Infected Human Brain.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:10, 2019
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:1, 2019
Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 21, Issue:2, 2019
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.BMC infectious diseases, , Feb-11, Volume: 19, Issue:1, 2019
Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:6, 2019
Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.The Journal of antimicrobial chemotherapy, , Jan-01, Volume: 73, Issue:1, 2018
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 24 Suppl 1, 2018
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.Journal de mycologie medicale, , Volume: 28, Issue:1, 2018
Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.Future microbiology, , Volume: 13, 2018
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.Drug design, development and therapy, , Volume: 12, 2018
Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.Diagnostic microbiology and infectious disease, , Volume: 92, Issue:1, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Clinical pharmacokinetics, , Volume: 57, Issue:12, 2018
Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.Current medical research and opinion, , Volume: 34, Issue:12, 2018
The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation.Critical care (London, England), , 12-22, Volume: 22, Issue:1, 2018
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.Mycoses, , Volume: 61, Issue:7, 2018
Isavuconazole: Case Report and Pharmacokinetic Considerations.Chemotherapy, , Volume: 63, Issue:5, 2018
Comparative evaluation of different gradient diffusion tests for detection of azole resistance in Aspergillus fumigatus.Diagnostic microbiology and infectious disease, , Volume: 91, Issue:1, 2018
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.Advances in therapy, , Volume: 34, Issue:1, 2017
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:6, 2017
Invasive mould infections in the ICU setting: complexities and solutions.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
New pharmacological opportunities for the treatment of invasive mould diseases.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:12, 2017
Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.Journal of medical economics, , Volume: 19, Issue:7, 2016
Isavuconazonium sulfate (Cresemba)--a new antifungal.The Medical letter on drugs and therapeutics, , Mar-14, Volume: 58, Issue:1490, 2016
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.The Lancet. Infectious diseases, , Volume: 16, Issue:7, 2016
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).Antimicrobial agents and chemotherapy, , Volume: 60, Issue:8, 2016
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:9, 2016
Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Drugs, , Volume: 76, Issue:17, 2016
Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Expert review of clinical pharmacology, , Volume: 9, Issue:7, 2016
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.Lancet (London, England), , Feb-20, Volume: 387, Issue:10020, 2016
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:5, 2015
Isavuconazonium: first global approval.Drugs, , Volume: 75, Issue:7, 2015
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.The Annals of pharmacotherapy, , Volume: 49, Issue:7, 2015
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Pharmacotherapy, , Volume: 35, Issue:11, 2015
EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:11, 2014
In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:11, 2014
Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:11, 2013
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:8, 2013
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Journal of clinical microbiology, , Volume: 51, Issue:8, 2013
Newer antifungal agents.Expert review of anti-infective therapy, , Volume: 9, Issue:3, 2011
In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.Mycoses, , Volume: 54, Issue:5, 2011
In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.Diagnostic microbiology and infectious disease, , Volume: 71, Issue:4, 2011
Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:8, 2006
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.The Journal of antimicrobial chemotherapy, , Volume: 58, Issue:6, 2006
[Invasive aspergillosis in solid organ transplantation].Revista iberoamericana de micologia, , Volume: 35, Issue:4
[Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].Revista iberoamericana de micologia, , Volume: 35, Issue:4
In vitro synergy of isavuconazole in combination with colistin against Candida auris.Scientific reports, , 12-08, Volume: 10, Issue:1, 2020
Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.Journal de mycologie medicale, , Volume: 28, Issue:2, 2018
Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.Microbial pathogenesis, , Volume: 115, 2018
Drug development challenges and strategies to address emerging and resistant fungal pathogens.Expert review of anti-infective therapy, , Volume: 15, Issue:6, 2017
Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:1, 2016
A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:3, 2015
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.The Annals of pharmacotherapy, , Volume: 49, Issue:7, 2015
Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.Mycopathologia, , Volume: 178, Issue:1-2, 2014
Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:11, 2013
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Journal of clinical microbiology, , Volume: 51, Issue:8, 2013
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.The Journal of antimicrobial chemotherapy, , Volume: 63, Issue:1, 2009
Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:8, 2009
Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:8, 2006
Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 06-16, Volume: 76, Issue:12, 2023
Isavuconazole as Salvage Therapy for Refractory Pediatric Coccidioidal Meningitis.The Pediatric infectious disease journal, , 03-01, Volume: 40, Issue:3, 2021
Isavuconazole in the Treatment of Coccidioidal Meningitis.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:3, 2019
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 08-01, Volume: 63, Issue:3, 2016
Coccidioidomycosis: Recent Updates.Seminars in respiratory and critical care medicine, , Volume: 36, Issue:5, 2015
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
Successful Isavuconazole Salvage Therapy for a Cryptococcus deuterogattii (AFLP6/VGII) Disseminated Infection in a European Immunocompetent Patient.Mycopathologia, , Volume: 186, Issue:4, 2021
Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.Mycopathologia, , Volume: 184, Issue:5, 2019
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 08-01, Volume: 63, Issue:3, 2016
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:1, 2015
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
Pulmonary infection secondary to Blastobotrys raffinosifermentans in a cystic fibrosis patient: Review of the literature.Mycoses, , Volume: 64, Issue:6, 2021
Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis.Clinical chemistry and laboratory medicine, , Oct-25, Volume: 57, Issue:11, 2019
Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 20, Issue:3, 2018
Improvement in Exophiala dermatitidis airway persistence and respiratory decline in response to interferon-gamma therapy in a patient with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, , Volume: 17, Issue:3, 2018
Use of isavuconazole in a patient with voriconazole-induced QTc prolongation.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 19, Issue:4, 2017
Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:6, 2019
Isavuconazole Diffusion in Infected Human Brain.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:10, 2019
Phellinus species: An emerging cause of refractory fungal infections in patients with X-linked chronic granulomatous disease.Mycoses, , Volume: 60, Issue:3, 2017
Disseminated histoplasmosis in an immunosuppressed patient successfully treated with isavuconazole.BMJ case reports, , Aug-18, Volume: 16, Issue:8, 2023
In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum.Medical mycology, , Oct-01, Volume: 56, Issue:7, 2018
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 08-01, Volume: 63, Issue:3, 2016
Successful isavuconazole salvage therapy for cerebral mucormycosis in a child with relapsed leukemia: A light in the dark tunnel.Pediatric blood & cancer, , Volume: 70, Issue:1, 2023
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.Mycoses, , Volume: 62, Issue:1, 2019
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-30, Volume: 67, Issue:10, 2018
Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.Journal of clinical pharmacology, , Volume: 58, Issue:10, 2018
Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:5, 2016
Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:11, 2009
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.Transplantation, , 03-01, Volume: 107, Issue:3, 2023
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology, , Volume: 14, 2023
Study of an antifungal medicine isavuconazole used in treatment of mold infections in China: A plain language summary.Future microbiology, , Volume: 18, 2023
Successful isavuconazole salvage therapy for cerebral mucormycosis in a child with relapsed leukemia: A light in the dark tunnel.Pediatric blood & cancer, , Volume: 70, Issue:1, 2023
Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India.Medical mycology, , Jul-06, Volume: 61, Issue:7, 2023
Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study.Medical mycology, , Apr-03, Volume: 61, Issue:4, 2023
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, , Volume: 120, 2022
A 67-Year-Old Male Patient With COVID-19 With Worsening Respiratory Function and Acute Kidney Failure.Chest, , Volume: 161, Issue:1, 2022
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.Mycoses, , Volume: 65, Issue:2, 2022
Colon mucormycosis with renal spread resistant to lipid complex amphotericin and isavuconazole treatment in a heart transplant recipient.Polish archives of internal medicine, , 01-28, Volume: 132, Issue:1, 2022
Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 09-15, Volume: 73, Issue:6, 2021
Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis.The Journal of antimicrobial chemotherapy, , 09-15, Volume: 76, Issue:10, 2021
The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.Mycoses, , Volume: 64, Issue:1, 2021
A 51-Year-Old Woman With a Mediastinal Mass.Chest, , Volume: 159, Issue:3, 2021
Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients.The Pediatric infectious disease journal, , Volume: 39, Issue:8, 2020
Primary cutaneous mucormycosis of the abdomen at the site of repeated insulin injections.BMJ case reports, , Feb-10, Volume: 13, Issue:2, 2020
Isolated cerebral mucormycosis associated with intravenous drug use.Journal de mycologie medicale, , Volume: 30, Issue:4, 2020
In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.The Journal of antimicrobial chemotherapy, , 07-01, Volume: 74, Issue:7, 2019
A Revised Species Concept for Opportunistic Antimicrobial agents and chemotherapy, , Volume: 63, Issue:8, 2019
Widespread Lichtheimia Infection in a Patient with Extensive Burns: Opportunities for Novel Antifungal Agents.Mycopathologia, , Volume: 184, Issue:1, 2019
Disseminated mucormycosis.Intensive care medicine, , Volume: 45, Issue:10, 2019
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.BMC infectious diseases, , Feb-11, Volume: 19, Issue:1, 2019
Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature.Mycopathologia, , Volume: 184, Issue:1, 2019
Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.Medical mycology, , Apr-01, Volume: 57, Issue:3, 2019
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.Mycoses, , Volume: 61, Issue:7, 2018
Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.Pediatric blood & cancer, , Volume: 65, Issue:10, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Clinical pharmacokinetics, , Volume: 57, Issue:12, 2018
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.European journal of drug metabolism and pharmacokinetics, , Volume: 43, Issue:3, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.Mycoses, , Volume: 61, Issue:7, 2018
Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.BMC pharmacology & toxicology, , Dec-06, Volume: 19, Issue:1, 2018
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.Journal de mycologie medicale, , Volume: 28, Issue:1, 2018
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.Drug design, development and therapy, , Volume: 12, 2018
Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.Future microbiology, , Volume: 13, 2018
Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.The Journal of antimicrobial chemotherapy, , Volume: 72, Issue:2, 2017
The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.Future microbiology, , Volume: 12, 2017
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:5, 2017
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:6, 2017
Invasive mould infections in the ICU setting: complexities and solutions.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
New pharmacological opportunities for the treatment of invasive mould diseases.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Isavuconazonium sulfate (Cresemba)--a new antifungal.The Medical letter on drugs and therapeutics, , Mar-14, Volume: 58, Issue:1490, 2016
Isavuconazole: an azole active against mucormycosis.The Lancet. Infectious diseases, , Volume: 16, Issue:7, 2016
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.The Lancet. Infectious diseases, , Volume: 16, Issue:7, 2016
Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Expert review of clinical pharmacology, , Volume: 9, Issue:7, 2016
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).Antimicrobial agents and chemotherapy, , Volume: 60, Issue:8, 2016
Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents.Current opinion in infectious diseases, , Volume: 29, Issue:4, 2016
Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.The Annals of pharmacotherapy, , Volume: 50, Issue:9, 2016
Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Drugs, , Volume: 76, Issue:17, 2016
Isavuconazonium: first global approval.Drugs, , Volume: 75, Issue:7, 2015
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Nov-15, Volume: 61, Issue:10, 2015
Mucormycosis: New Developments into a Persistently Devastating Infection.Seminars in respiratory and critical care medicine, , Volume: 36, Issue:5, 2015
Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Pharmacotherapy, , Volume: 35, Issue:11, 2015
Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.Infection, , Volume: 42, Issue:2, 2014
Isavuconazole treatment of a patient with disseminated mucormycosis.Journal of clinical microbiology, , Volume: 52, Issue:3, 2014
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:4, 2014
Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery.The Journal of antimicrobial chemotherapy, , Volume: 69, Issue:12, 2014
In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:11, 2014
Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.Mycoses, , Volume: 57 Suppl 3, 2014
Part 2: mucormycosis: focus on therapy.Expert review of anti-infective therapy, , Volume: 21, Issue:7
A unique case of upper GI bleed.Acta gastro-enterologica Belgica, , Volume: 80, Issue:4
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25, Issue:2, 2023
Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses.Journal of clinical pharmacology, , Volume: 63, Issue:6, 2023
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology, , Volume: 14, 2023
A plain language summary on preventing fungal infections with isavuconazole in people with blood-related conditions.Future microbiology, , Volume: 18, 2023
Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).Microbiology spectrum, , 02-23, Volume: 10, Issue:1, 2022
Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.Future microbiology, , Volume: 17, 2022
Pulmonary infection secondary to Blastobotrys raffinosifermentans in a cystic fibrosis patient: Review of the literature.Mycoses, , Volume: 64, Issue:6, 2021
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-18, Volume: 72, Issue:10, 2021
Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.Medical mycology, , Oct-01, Volume: 58, Issue:7, 2020
Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 26, Issue:11, 2020
In vitro activity of isavuconazole against clinically isolated yeasts from Chile.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], , Volume: 51, Issue:4, 2020
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia.Mycopathologia, , Volume: 185, Issue:3, 2020
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.Mycoses, , Volume: 62, Issue:1, 2019
Real-world use-Isavuconazole at a large academic medical center.Mycoses, , Volume: 62, Issue:6, 2019
Evaluation of isavuconazole MIC strips for susceptibility testing of Aspergillus and Scedosporium species.Medical mycology, , Jun-01, Volume: 57, Issue:4, 2019
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.Mycoses, , Volume: 61, Issue:7, 2018
Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.Diagnostic microbiology and infectious disease, , Volume: 92, Issue:1, 2018
Isavuconazole: is there a need for a new antifungal?The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 08-01, Volume: 63, Issue:3, 2016
Isavuconazonium sulfate (Cresemba)--a new antifungal.The Medical letter on drugs and therapeutics, , Mar-14, Volume: 58, Issue:1490, 2016
Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.Journal of medical economics, , Volume: 19, Issue:7, 2016
Isavuconazonium sulfate for the treatment of fungal infection.Drugs of today (Barcelona, Spain : 1998), , Volume: 52, Issue:1, 2016
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.Lancet (London, England), , Feb-20, Volume: 387, Issue:10020, 2016
Isavuconazole: a role for the newest broad-spectrum triazole.Lancet (London, England), , Feb-20, Volume: 387, Issue:10020, 2016
Dosing of antifungal agents in obese people.Expert review of anti-infective therapy, , Volume: 14, Issue:2, 2016
[NEW ANTIFUNGAL DRUGS FOR PREVENTION AND TREATMENT OF VISCERAL MYCOSES].La Revue du praticien, , Volume: 65, Issue:10, 2015
In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Expert opinion on pharmacotherapy, , Volume: 16, Issue:10, 2015
Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Future microbiology, , Volume: 10, Issue:5, 2015
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and propDiagnostic microbiology and infectious disease, , Volume: 82, Issue:4, 2015
Isavuconazonium sulfate approved for invasive fungal infections.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Apr-15, Volume: 72, Issue:8, 2015
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:4, 2015
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Expert review of anti-infective therapy, , Volume: 13, Issue:1, 2015
Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.Journal of clinical microbiology, , Volume: 51, Issue:9, 2013
[Recent advances in the study of new antifungal lead compounds].Yao xue xue bao = Acta pharmaceutica Sinica, , Volume: 45, Issue:8, 2010
In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.International journal of antimicrobial agents, , Volume: 36, Issue:4, 2010
Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.Mycopathologia, , Volume: 170, Issue:5, 2010
Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.Current opinion in investigational drugs (London, England : 2000), , Volume: 11, Issue:2, 2010
In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.The Journal of antimicrobial chemotherapy, , Volume: 64, Issue:1, 2009
In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.Medical mycology, , Volume: 47, Issue:1, 2009
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.Future microbiology, , Volume: 3, Issue:6, 2008
[Pharmacological profile of isavuconazole].Revista iberoamericana de micologia, , Volume: 35, Issue:4
[no title available]Therapeutische Umschau. Revue therapeutique, , Volume: 73, Issue:8
Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome.American journal of otolaryngology, , Volume: 37, Issue:2
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-18, Volume: 72, Issue:10, 2021
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 24 Suppl 1, 2018
Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube.The Journal of antimicrobial chemotherapy, , Dec-01, Volume: 78, Issue:12, 2023
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.Mycoses, , Volume: 66, Issue:5, 2023
Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological MalignanciTherapeutic drug monitoring, , 10-01, Volume: 44, Issue:5, 2022
Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.Microbial pathogenesis, , Volume: 115, 2018
Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.Mycoses, , Volume: 61, Issue:3, 2018
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 73, Issue:3, 2018
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:4, 2015
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.The Journal of antimicrobial chemotherapy, , Volume: 63, Issue:1, 2009
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.The Journal of antimicrobial chemotherapy, , Volume: 58, Issue:6, 2006
A Rare Case of Journal of investigative medicine high impact case reports, , Volume: 8
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25, Issue:2, 2023
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-29, Volume: 75, Issue:9, 2022
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-18, Volume: 72, Issue:10, 2021
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia.Mycopathologia, , Volume: 185, Issue:3, 2020
Conidiobolus pachyzygosporus invasive pulmonary infection in a patient with acute myeloid leukemia: case report and review of the literature.BMC infectious diseases, , Jul-22, Volume: 20, Issue:1, 2020
Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients.Emerging infectious diseases, , Volume: 25, Issue:9, 2019
Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 25, Issue:4, 2019
Hepatic veno-occlusive disease during isavuconazole administration.Journal of chemotherapy (Florence, Italy), , Volume: 30, Issue:1, 2018
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 24 Suppl 1, 2018
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:4, 2015
Isavuconazole treatment of a patient with disseminated mucormycosis.Journal of clinical microbiology, , Volume: 52, Issue:3, 2014
A Rare Case of Journal of investigative medicine high impact case reports, , Volume: 8
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:9, 2019
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:9, 2016
A Rare Case of Journal of investigative medicine high impact case reports, , Volume: 8
Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25 Suppl 1, 2023
Isavuconazole as an alternative for antifungal prophylaxis in patients with hematological malignancies: Is the signal sufficient to support clinical practice?Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25, Issue:2, 2023
Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-14, Volume: 70, Issue:5, 2020
Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience.Journal of pediatric hematology/oncology, , Volume: 42, Issue:4, 2020
A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.Antimicrobial agents and chemotherapy, , 02-21, Volume: 64, Issue:3, 2020
Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-15, Volume: 69, Issue:9, 2019
Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature.Journal of pediatric hematology/oncology, , Volume: 42, Issue:6, 2020
Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature.Mycopathologia, , Volume: 184, Issue:1, 2019
Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.Pediatric blood & cancer, , Volume: 65, Issue:10, 2018
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
A 67-Year-Old Male Patient With COVID-19 With Worsening Respiratory Function and Acute Kidney Failure.Chest, , Volume: 161, Issue:1, 2022
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.The Lancet. Infectious diseases, , Volume: 21, Issue:6, 2021
Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature.Journal of pediatric hematology/oncology, , Volume: 42, Issue:6, 2020
An overview of the available treatments for chronic cavitary pulmonary aspergillosis.Expert review of respiratory medicine, , Volume: 14, Issue:7, 2020
COVID-19 associated pulmonary aspergillosis.Mycoses, , Volume: 63, Issue:6, 2020
Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.Mycoses, , Volume: 62, Issue:3, 2019
Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients.Emerging infectious diseases, , Volume: 25, Issue:9, 2019
The spectrum of pulmonary aspergillosis.Respiratory medicine, , Volume: 141, 2018
Graded isavuconazole introduction in a patient with voriconazole allergy.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 19, Issue:6, 2017
Successful Treatment of Chronic Pulmonary Aspergillosis With Isavuconazole.Journal of investigational allergology & clinical immunology, , Volume: 29, Issue:6
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-29, Volume: 75, Issue:9, 2022
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.Mycoses, , Volume: 62, Issue:1, 2019
Isavuconazole: Case Report and Pharmacokinetic Considerations.Chemotherapy, , Volume: 63, Issue:5, 2018
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Isavuconazole and Liposomal Amphotericin B as Successful Combination Therapy of Refractory Invasive Candidiasis in a Liver Transplant Recipient: A Case Report and Literature Review.Mycopathologia, , Volume: 187, Issue:1, 2022
New Perspectives on Antimicrobial Agents: Isavuconazole.Antimicrobial agents and chemotherapy, , 09-20, Volume: 66, Issue:9, 2022
Antifungal drugs work together to treat germs causing fungal infections.Future microbiology, , Volume: 16, 2021
Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-30, Volume: 68, Issue:12, 2019
Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-30, Volume: 68, Issue:12, 2019
In vitro combination therapy with isavuconazole against Candida spp.Medical mycology, , Nov-01, Volume: 55, Issue:8, 2017
Dosing of antifungal agents in obese people.Expert review of anti-infective therapy, , Volume: 14, Issue:2, 2016
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Pharmacotherapy, , Volume: 35, Issue:11, 2015
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.The Annals of pharmacotherapy, , Volume: 49, Issue:7, 2015
Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:11, 2013
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.Expert opinion on drug metabolism & toxicology, , Volume: 8, Issue:6, 2012
Newer antifungal agents.Expert review of anti-infective therapy, , Volume: 9, Issue:3, 2011
[Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].Revista iberoamericana de micologia, , Volume: 35, Issue:4
Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-30, Volume: 68, Issue:12, 2019
Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-30, Volume: 68, Issue:12, 2019
Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 24, Issue:12, 2018
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.Journal de mycologie medicale, , Volume: 28, Issue:1, 2018
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-30, Volume: 67, Issue:10, 2018
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Pharmacotherapy, , Volume: 35, Issue:11, 2015
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.The Annals of pharmacotherapy, , Volume: 49, Issue:7, 2015
Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study.Therapeutic drug monitoring, , 04-01, Volume: 45, Issue:2, 2023
Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.Future microbiology, , Volume: 17, 2022
Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.Medical mycology, , Oct-01, Volume: 58, Issue:7, 2020
Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature.Mycopathologia, , Volume: 184, Issue:1, 2019
Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.The Journal of antimicrobial chemotherapy, , 08-01, Volume: 74, Issue:8, 2019
Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.Mycoses, , Volume: 62, Issue:3, 2019
Real-world use-Isavuconazole at a large academic medical center.Mycoses, , Volume: 62, Issue:6, 2019
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.Mycoses, , Volume: 62, Issue:1, 2019
Isavuconazole for treatment of rare invasive fungal diseases.Mycoses, , Volume: 61, Issue:8, 2018
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.Mycoses, , Volume: 61, Issue:7, 2018
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Nov-15, Volume: 61, Issue:10, 2015
Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:8, 2006
Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25 Suppl 1, 2023
Isavuconazole as an alternative for antifungal prophylaxis in patients with hematological malignancies: Is the signal sufficient to support clinical practice?Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25, Issue:2, 2023
Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-14, Volume: 70, Issue:5, 2020
Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience.Journal of pediatric hematology/oncology, , Volume: 42, Issue:4, 2020
A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.Antimicrobial agents and chemotherapy, , 02-21, Volume: 64, Issue:3, 2020
Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-15, Volume: 69, Issue:9, 2019
A Rare Case of Journal of investigative medicine high impact case reports, , Volume: 8
Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature.Journal of pediatric hematology/oncology, , Volume: 42, Issue:6, 2020
Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature.Mycopathologia, , Volume: 184, Issue:1, 2019
Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.Pediatric blood & cancer, , Volume: 65, Issue:10, 2018
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
A 67-Year-Old Male Patient With COVID-19 With Worsening Respiratory Function and Acute Kidney Failure.Chest, , Volume: 161, Issue:1, 2022
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.The Lancet. Infectious diseases, , Volume: 21, Issue:6, 2021
COVID-19 associated pulmonary aspergillosis.Mycoses, , Volume: 63, Issue:6, 2020
An overview of the available treatments for chronic cavitary pulmonary aspergillosis.Expert review of respiratory medicine, , Volume: 14, Issue:7, 2020
Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature.Journal of pediatric hematology/oncology, , Volume: 42, Issue:6, 2020
Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.Mycoses, , Volume: 62, Issue:3, 2019
Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients.Emerging infectious diseases, , Volume: 25, Issue:9, 2019
The spectrum of pulmonary aspergillosis.Respiratory medicine, , Volume: 141, 2018
Graded isavuconazole introduction in a patient with voriconazole allergy.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 19, Issue:6, 2017
Successful Treatment of Chronic Pulmonary Aspergillosis With Isavuconazole.Journal of investigational allergology & clinical immunology, , Volume: 29, Issue:6
Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada.Expert review of pharmacoeconomics & outcomes research, , Volume: 22, Issue:5, 2022
Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 23, Issue:2, 2021
Isavuconazole-induced Acute Liver Failure in a Pediatric Patient With Invasive Aspergillosis.The Pediatric infectious disease journal, , Volume: 38, Issue:10, 2019
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 24 Suppl 1, 2018
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 73, Issue:3, 2018
The spectrum of pulmonary aspergillosis.Respiratory medicine, , Volume: 141, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.Mycoses, , Volume: 61, Issue:7, 2018
High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis.European journal of clinical pharmacology, , Volume: 74, Issue:8, 2018
Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.Mycoses, , Volume: 61, Issue:3, 2018
In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.The Journal of antimicrobial chemotherapy, , 09-01, Volume: 72, Issue:9, 2017
Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.Expert review of respiratory medicine, , Volume: 11, Issue:9, 2017
Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Jun-01, Volume: 64, Issue:11, 2017
Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:9, 2017
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.The Journal of antimicrobial chemotherapy, , Volume: 71, Issue:7, 2016
Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:5, 2016
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Nov-15, Volume: 61, Issue:10, 2015
Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:12, 2013
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.Expert opinion on drug metabolism & toxicology, , Volume: 8, Issue:6, 2012
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-29, Volume: 75, Issue:9, 2022
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.Mycoses, , Volume: 62, Issue:1, 2019
Isavuconazole: Case Report and Pharmacokinetic Considerations.Chemotherapy, , Volume: 63, Issue:5, 2018
Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of Exserohilum rostratum meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis.Medical mycology, , Feb-04, Volume: 59, Issue:2, 2021
[Treatment of chromoblastomycosis and phaeohyphomycosis].Klinicka mikrobiologie a infekcni lekarstvi, , Volume: 26, Issue:2, 2020
Successful treatment with isavuconazole of subcutaneous phaeohyphomycosis in a kidney transplant recipient.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 21, Issue:6, 2019
Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study.Therapeutic drug monitoring, , 04-01, Volume: 45, Issue:2, 2023
Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.Future microbiology, , Volume: 17, 2022
Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.Medical mycology, , Oct-01, Volume: 58, Issue:7, 2020
Real-world use-Isavuconazole at a large academic medical center.Mycoses, , Volume: 62, Issue:6, 2019
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.Mycoses, , Volume: 62, Issue:1, 2019
Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature.Mycopathologia, , Volume: 184, Issue:1, 2019
Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.The Journal of antimicrobial chemotherapy, , 08-01, Volume: 74, Issue:8, 2019
Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.Mycoses, , Volume: 62, Issue:3, 2019
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.Mycoses, , Volume: 61, Issue:7, 2018
Isavuconazole for treatment of rare invasive fungal diseases.Mycoses, , Volume: 61, Issue:8, 2018
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Nov-15, Volume: 61, Issue:10, 2015
Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:8, 2006
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.Transplantation, , 03-01, Volume: 107, Issue:3, 2023
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.Mycoses, , Volume: 66, Issue:5, 2023
A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.Mycoses, , Volume: 66, Issue:9, 2023
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25, Issue:2, 2023
Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25 Suppl 1, 2023
Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study.Medical mycology, , Apr-03, Volume: 61, Issue:4, 2023
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.Scientific reports, , 04-25, Volume: 13, Issue:1, 2023
New Perspectives on Antimicrobial Agents: Isavuconazole.Antimicrobial agents and chemotherapy, , 09-20, Volume: 66, Issue:9, 2022
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.Future microbiology, , Volume: 17, 2022
Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting.Hematology (Amsterdam, Netherlands), , Volume: 27, Issue:1, 2022
Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , 07-22, Volume: 79, Issue:15, 2022
Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological MalignanciTherapeutic drug monitoring, , 10-01, Volume: 44, Issue:5, 2022
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-29, Volume: 75, Issue:9, 2022
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.Mycoses, , Volume: 65, Issue:2, 2022
Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.Journal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients.Antimicrobial agents and chemotherapy, , 07-16, Volume: 65, Issue:8, 2021
Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series.Journal of clinical pharmacy and therapeutics, , Volume: 46, Issue:2, 2021
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.Mycoses, , Volume: 64, Issue:4, 2021
Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 23, Issue:2, 2021
Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 09-15, Volume: 73, Issue:6, 2021
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia.Mycopathologia, , Volume: 185, Issue:3, 2020
Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience.Journal of pediatric hematology/oncology, , Volume: 42, Issue:4, 2020
The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.Journal of medical economics, , Volume: 23, Issue:1, 2020
Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.Mycoses, , Volume: 63, Issue:1, 2020
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.Medical mycology, , Jun-01, Volume: 58, Issue:4, 2020
A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, , Volume: 26, Issue:6, 2020
A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.Antimicrobial agents and chemotherapy, , 02-21, Volume: 64, Issue:3, 2020
Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient.Mycopathologia, , Volume: 185, Issue:2, 2020
Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.Mycoses, , Volume: 62, Issue:8, 2019
Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:6, 2019
Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.Annals of clinical microbiology and antimicrobials, , Mar-20, Volume: 18, Issue:1, 2019
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.BMC infectious diseases, , Feb-11, Volume: 19, Issue:1, 2019
Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 21, Issue:2, 2019
Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.Mycopathologia, , Volume: 184, Issue:5, 2019
Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature.Mycopathologia, , Volume: 184, Issue:1, 2019
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 74, Issue:3, 2019
Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 25, Issue:5, 2019
Real-life use of isavuconazole outside the hematological wards.European journal of internal medicine, , Volume: 70, 2019
Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.Leukemia & lymphoma, , Volume: 60, Issue:2, 2019
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:1, 2019
Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.The Journal of antimicrobial chemotherapy, , 08-01, Volume: 74, Issue:8, 2019
Isavuconazole shortens the QTc interval.Mycoses, , Volume: 61, Issue:4, 2018
The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation.Critical care (London, England), , 12-22, Volume: 22, Issue:1, 2018
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.Journal de mycologie medicale, , Volume: 28, Issue:1, 2018
Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 09-14, Volume: 67, Issue:7, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.Mycoses, , Volume: 61, Issue:7, 2018
Isavuconazole for treatment of rare invasive fungal diseases.Mycoses, , Volume: 61, Issue:8, 2018
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-30, Volume: 67, Issue:10, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Clinical pharmacokinetics, , Volume: 57, Issue:12, 2018
Hepatic veno-occlusive disease during isavuconazole administration.Journal of chemotherapy (Florence, Italy), , Volume: 30, Issue:1, 2018
Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.Mycoses, , Volume: 61, Issue:11, 2018
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.Mycoses, , Volume: 61, Issue:7, 2018
Drug development challenges and strategies to address emerging and resistant fungal pathogens.Expert review of anti-infective therapy, , Volume: 15, Issue:6, 2017
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:6, 2017
Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Jun-01, Volume: 64, Issue:11, 2017
The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.Future microbiology, , Volume: 12, 2017
Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jan-01, Volume: 74, Issue:1, 2017
An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.Expert opinion on drug safety, , Volume: 16, Issue:3, 2017
Phellinus species: An emerging cause of refractory fungal infections in patients with X-linked chronic granulomatous disease.Mycoses, , Volume: 60, Issue:3, 2017
Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.The International journal of pharmacy practice, , Volume: 25, Issue:1, 2017
New pharmacological opportunities for the treatment of invasive mould diseases.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:12, 2017
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Invasive mould infections in the ICU setting: complexities and solutions.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Expert review of clinical pharmacology, , Volume: 9, Issue:7, 2016
[Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].Revista iberoamericana de micologia, , Volume: 35, Issue:4
[Invasive aspergillosis in solid organ transplantation].Revista iberoamericana de micologia, , Volume: 35, Issue:4
Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India.Medical mycology, , Jul-06, Volume: 61, Issue:7, 2023
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology, , Volume: 14, 2023
A 67-Year-Old Male Patient With COVID-19 With Worsening Respiratory Function and Acute Kidney Failure.Chest, , Volume: 161, Issue:1, 2022
Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, , Volume: 120, 2022
Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.The Journal of antimicrobial chemotherapy, , 08-25, Volume: 77, Issue:9, 2022
Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 23, Issue:2, 2021
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.The Lancet. Infectious diseases, , Volume: 21, Issue:6, 2021
COVID-19 associated pulmonary aspergillosis.Mycoses, , Volume: 63, Issue:6, 2020
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.Scientific reports, , 04-25, Volume: 13, Issue:1, 2023
Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study.Medical mycology, , Apr-03, Volume: 61, Issue:4, 2023
Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study.Therapeutic drug monitoring, , 04-01, Volume: 45, Issue:2, 2023
Study of an antifungal medicine isavuconazole used in treatment of mold infections in China: A plain language summary.Future microbiology, , Volume: 18, 2023
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.Transplantation, , 03-01, Volume: 107, Issue:3, 2023
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.Mycoses, , Volume: 66, Issue:5, 2023
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.Future microbiology, , Volume: 17, 2022
Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , 07-22, Volume: 79, Issue:15, 2022
Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).Microbiology spectrum, , 02-23, Volume: 10, Issue:1, 2022
Efficacy and safety of Isavuconazole for the treatment of invasive Expert opinion on pharmacotherapy, , Volume: 23, Issue:5, 2022
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.Mycoses, , Volume: 65, Issue:2, 2022
Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada.Expert review of pharmacoeconomics & outcomes research, , Volume: 22, Issue:5, 2022
Broad-spectrum azoles and flucloxacillin: a dangerous match.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, , Volume: 41, Issue:1, 2022
Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 09-15, Volume: 73, Issue:6, 2021
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.Mycoses, , Volume: 64, Issue:4, 2021
The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.Mycoses, , Volume: 64, Issue:1, 2021
Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.Mycoses, , Volume: 63, Issue:1, 2020
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.Diagnostic microbiology and infectious disease, , Volume: 97, Issue:1, 2020
Intravenous isavuconazole can be administered 5 days-a-week. A possibility suggested by a real-life observation.Journal of chemotherapy (Florence, Italy), , Volume: 32, Issue:4, 2020
Ibrutinib related cerebral aspergillosis successfully treated with isavuconazole: a case report.Leukemia & lymphoma, , Volume: 61, Issue:7, 2020
Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient.Mycopathologia, , Volume: 185, Issue:2, 2020
Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation.Chemotherapy, , Volume: 64, Issue:2, 2019
Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:11, 2019
Isavuconazole Diffusion in Infected Human Brain.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:10, 2019
Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:6, 2019
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.BMC infectious diseases, , Feb-11, Volume: 19, Issue:1, 2019
Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 21, Issue:2, 2019
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 74, Issue:3, 2019
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:1, 2019
The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation.Critical care (London, England), , 12-22, Volume: 22, Issue:1, 2018
Isavuconazole: Case Report and Pharmacokinetic Considerations.Chemotherapy, , Volume: 63, Issue:5, 2018
Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.Current medical research and opinion, , Volume: 34, Issue:12, 2018
Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.Future microbiology, , Volume: 13, 2018
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.Drug design, development and therapy, , Volume: 12, 2018
Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.Diagnostic microbiology and infectious disease, , Volume: 92, Issue:1, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Clinical pharmacokinetics, , Volume: 57, Issue:12, 2018
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.Mycoses, , Volume: 61, Issue:7, 2018
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.Journal de mycologie medicale, , Volume: 28, Issue:1, 2018
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 24 Suppl 1, 2018
Comparative evaluation of different gradient diffusion tests for detection of azole resistance in Aspergillus fumigatus.Diagnostic microbiology and infectious disease, , Volume: 91, Issue:1, 2018
Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.The Journal of antimicrobial chemotherapy, , Jan-01, Volume: 73, Issue:1, 2018
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:6, 2017
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.Advances in therapy, , Volume: 34, Issue:1, 2017
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:12, 2017
New pharmacological opportunities for the treatment of invasive mould diseases.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Invasive mould infections in the ICU setting: complexities and solutions.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.The Lancet. Infectious diseases, , Volume: 16, Issue:7, 2016
Isavuconazonium sulfate (Cresemba)--a new antifungal.The Medical letter on drugs and therapeutics, , Mar-14, Volume: 58, Issue:1490, 2016
Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.Journal of medical economics, , Volume: 19, Issue:7, 2016
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.Lancet (London, England), , Feb-20, Volume: 387, Issue:10020, 2016
Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Drugs, , Volume: 76, Issue:17, 2016
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:9, 2016
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).Antimicrobial agents and chemotherapy, , Volume: 60, Issue:8, 2016
Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Expert review of clinical pharmacology, , Volume: 9, Issue:7, 2016
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Pharmacotherapy, , Volume: 35, Issue:11, 2015
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.The Annals of pharmacotherapy, , Volume: 49, Issue:7, 2015
Isavuconazonium: first global approval.Drugs, , Volume: 75, Issue:7, 2015
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:5, 2015
In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:11, 2014
EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:11, 2014
Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:11, 2013
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Journal of clinical microbiology, , Volume: 51, Issue:8, 2013
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:8, 2013
In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.Diagnostic microbiology and infectious disease, , Volume: 71, Issue:4, 2011
In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.Mycoses, , Volume: 54, Issue:5, 2011
Newer antifungal agents.Expert review of anti-infective therapy, , Volume: 9, Issue:3, 2011
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.The Journal of antimicrobial chemotherapy, , Volume: 58, Issue:6, 2006
Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:8, 2006
[Invasive aspergillosis in solid organ transplantation].Revista iberoamericana de micologia, , Volume: 35, Issue:4
[Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].Revista iberoamericana de micologia, , Volume: 35, Issue:4
In vitro synergy of isavuconazole in combination with colistin against Candida auris.Scientific reports, , 12-08, Volume: 10, Issue:1, 2020
Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.Microbial pathogenesis, , Volume: 115, 2018
Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.Journal de mycologie medicale, , Volume: 28, Issue:2, 2018
Drug development challenges and strategies to address emerging and resistant fungal pathogens.Expert review of anti-infective therapy, , Volume: 15, Issue:6, 2017
Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:1, 2016
A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:3, 2015
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.The Annals of pharmacotherapy, , Volume: 49, Issue:7, 2015
Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.Mycopathologia, , Volume: 178, Issue:1-2, 2014
Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:11, 2013
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Journal of clinical microbiology, , Volume: 51, Issue:8, 2013
Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:8, 2009
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.The Journal of antimicrobial chemotherapy, , Volume: 63, Issue:1, 2009
Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:8, 2006
[Treatment of chromoblastomycosis and phaeohyphomycosis].Klinicka mikrobiologie a infekcni lekarstvi, , Volume: 26, Issue:2, 2020
In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:4, 2013
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:4, 2010
Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 06-16, Volume: 76, Issue:12, 2023
Isavuconazole as Salvage Therapy for Refractory Pediatric Coccidioidal Meningitis.The Pediatric infectious disease journal, , 03-01, Volume: 40, Issue:3, 2021
Isavuconazole in the Treatment of Coccidioidal Meningitis.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:3, 2019
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 08-01, Volume: 63, Issue:3, 2016
Coccidioidomycosis: Recent Updates.Seminars in respiratory and critical care medicine, , Volume: 36, Issue:5, 2015
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
Successful Isavuconazole Salvage Therapy for a Cryptococcus deuterogattii (AFLP6/VGII) Disseminated Infection in a European Immunocompetent Patient.Mycopathologia, , Volume: 186, Issue:4, 2021
Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.Mycopathologia, , Volume: 184, Issue:5, 2019
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 08-01, Volume: 63, Issue:3, 2016
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:1, 2015
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
Pulmonary infection secondary to Blastobotrys raffinosifermentans in a cystic fibrosis patient: Review of the literature.Mycoses, , Volume: 64, Issue:6, 2021
Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis.Clinical chemistry and laboratory medicine, , Oct-25, Volume: 57, Issue:11, 2019
Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 20, Issue:3, 2018
Improvement in Exophiala dermatitidis airway persistence and respiratory decline in response to interferon-gamma therapy in a patient with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, , Volume: 17, Issue:3, 2018
Use of isavuconazole in a patient with voriconazole-induced QTc prolongation.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 19, Issue:4, 2017
Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of Exserohilum rostratum meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis.Medical mycology, , Feb-04, Volume: 59, Issue:2, 2021
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.Medical mycology, , Apr-01, Volume: 57, Issue:3, 2019
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:9, 2019
Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:6, 2019
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:5, 2017
CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).PLoS neglected tropical diseases, , Volume: 11, Issue:12, 2017
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:9, 2016
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.The Journal of antimicrobial chemotherapy, , Volume: 71, Issue:7, 2016
Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:11, 2013
Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.Mycopathologia, , Volume: 170, Issue:5, 2010
Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.Future microbiology, , Volume: 3, Issue:6, 2008
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.The Journal of antimicrobial chemotherapy, , Volume: 58, Issue:6, 2006
Isavuconazole Diffusion in Infected Human Brain.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:10, 2019
Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:6, 2019
Phellinus species: An emerging cause of refractory fungal infections in patients with X-linked chronic granulomatous disease.Mycoses, , Volume: 60, Issue:3, 2017
Disseminated histoplasmosis in an immunosuppressed patient successfully treated with isavuconazole.BMJ case reports, , Aug-18, Volume: 16, Issue:8, 2023
In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum.Medical mycology, , Oct-01, Volume: 56, Issue:7, 2018
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 08-01, Volume: 63, Issue:3, 2016
Successful isavuconazole salvage therapy for cerebral mucormycosis in a child with relapsed leukemia: A light in the dark tunnel.Pediatric blood & cancer, , Volume: 70, Issue:1, 2023
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.Mycoses, , Volume: 62, Issue:1, 2019
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-30, Volume: 67, Issue:10, 2018
Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.Journal of clinical pharmacology, , Volume: 58, Issue:10, 2018
Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:5, 2016
Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:11, 2009
Conidiobolus pachyzygosporus invasive pulmonary infection in a patient with acute myeloid leukemia: case report and review of the literature.BMC infectious diseases, , Jul-22, Volume: 20, Issue:1, 2020
Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.Mycopathologia, , Volume: 184, Issue:5, 2019
Improvement in Exophiala dermatitidis airway persistence and respiratory decline in response to interferon-gamma therapy in a patient with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, , Volume: 17, Issue:3, 2018
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:5, 2017
Invasive mould infections in the ICU setting: complexities and solutions.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Mucormycosis: New Developments into a Persistently Devastating Infection.Seminars in respiratory and critical care medicine, , Volume: 36, Issue:5, 2015
Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery.The Journal of antimicrobial chemotherapy, , Volume: 69, Issue:12, 2014
Successful isavuconazole salvage therapy for cerebral mucormycosis in a child with relapsed leukemia: A light in the dark tunnel.Pediatric blood & cancer, , Volume: 70, Issue:1, 2023
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2, 2023
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.Transplantation, , 03-01, Volume: 107, Issue:3, 2023
Study of an antifungal medicine isavuconazole used in treatment of mold infections in China: A plain language summary.Future microbiology, , Volume: 18, 2023
Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study.Medical mycology, , Apr-03, Volume: 61, Issue:4, 2023
Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India.Medical mycology, , Jul-06, Volume: 61, Issue:7, 2023
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology, , Volume: 14, 2023
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.Mycoses, , Volume: 65, Issue:2, 2022
A 67-Year-Old Male Patient With COVID-19 With Worsening Respiratory Function and Acute Kidney Failure.Chest, , Volume: 161, Issue:1, 2022
Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, , Volume: 120, 2022
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Colon mucormycosis with renal spread resistant to lipid complex amphotericin and isavuconazole treatment in a heart transplant recipient.Polish archives of internal medicine, , 01-28, Volume: 132, Issue:1, 2022
The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.Mycoses, , Volume: 64, Issue:1, 2021
A 51-Year-Old Woman With a Mediastinal Mass.Chest, , Volume: 159, Issue:3, 2021
Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 09-15, Volume: 73, Issue:6, 2021
Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis.The Journal of antimicrobial chemotherapy, , 09-15, Volume: 76, Issue:10, 2021
Primary cutaneous mucormycosis of the abdomen at the site of repeated insulin injections.BMJ case reports, , Feb-10, Volume: 13, Issue:2, 2020
Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients.The Pediatric infectious disease journal, , Volume: 39, Issue:8, 2020
Isolated cerebral mucormycosis associated with intravenous drug use.Journal de mycologie medicale, , Volume: 30, Issue:4, 2020
Disseminated mucormycosis.Intensive care medicine, , Volume: 45, Issue:10, 2019
In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.The Journal of antimicrobial chemotherapy, , 07-01, Volume: 74, Issue:7, 2019
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.BMC infectious diseases, , Feb-11, Volume: 19, Issue:1, 2019
Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature.Mycopathologia, , Volume: 184, Issue:1, 2019
Widespread Lichtheimia Infection in a Patient with Extensive Burns: Opportunities for Novel Antifungal Agents.Mycopathologia, , Volume: 184, Issue:1, 2019
Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.Medical mycology, , Apr-01, Volume: 57, Issue:3, 2019
A Revised Species Concept for Opportunistic Antimicrobial agents and chemotherapy, , Volume: 63, Issue:8, 2019
Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.BMC pharmacology & toxicology, , Dec-06, Volume: 19, Issue:1, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.Mycoses, , Volume: 61, Issue:7, 2018
Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.Pediatric blood & cancer, , Volume: 65, Issue:10, 2018
Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.Future microbiology, , Volume: 13, 2018
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.Journal de mycologie medicale, , Volume: 28, Issue:1, 2018
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.Drug design, development and therapy, , Volume: 12, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Clinical pharmacokinetics, , Volume: 57, Issue:12, 2018
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.European journal of drug metabolism and pharmacokinetics, , Volume: 43, Issue:3, 2018
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.Mycoses, , Volume: 61, Issue:7, 2018
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:6, 2017
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:5, 2017
The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.Future microbiology, , Volume: 12, 2017
Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.The Journal of antimicrobial chemotherapy, , Volume: 72, Issue:2, 2017
Invasive mould infections in the ICU setting: complexities and solutions.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
New pharmacological opportunities for the treatment of invasive mould diseases.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Drugs, , Volume: 76, Issue:17, 2016
Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.The Annals of pharmacotherapy, , Volume: 50, Issue:9, 2016
Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents.Current opinion in infectious diseases, , Volume: 29, Issue:4, 2016
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).Antimicrobial agents and chemotherapy, , Volume: 60, Issue:8, 2016
Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Expert review of clinical pharmacology, , Volume: 9, Issue:7, 2016
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.The Lancet. Infectious diseases, , Volume: 16, Issue:7, 2016
Isavuconazole: an azole active against mucormycosis.The Lancet. Infectious diseases, , Volume: 16, Issue:7, 2016
Isavuconazonium sulfate (Cresemba)--a new antifungal.The Medical letter on drugs and therapeutics, , Mar-14, Volume: 58, Issue:1490, 2016
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Pharmacotherapy, , Volume: 35, Issue:11, 2015
In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Mucormycosis: New Developments into a Persistently Devastating Infection.Seminars in respiratory and critical care medicine, , Volume: 36, Issue:5, 2015
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Nov-15, Volume: 61, Issue:10, 2015
Isavuconazonium: first global approval.Drugs, , Volume: 75, Issue:7, 2015
Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.Mycoses, , Volume: 57 Suppl 3, 2014
In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:11, 2014
Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery.The Journal of antimicrobial chemotherapy, , Volume: 69, Issue:12, 2014
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:4, 2014
Isavuconazole treatment of a patient with disseminated mucormycosis.Journal of clinical microbiology, , Volume: 52, Issue:3, 2014
Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.Infection, , Volume: 42, Issue:2, 2014
Part 2: mucormycosis: focus on therapy.Expert review of anti-infective therapy, , Volume: 21, Issue:7
A unique case of upper GI bleed.Acta gastro-enterologica Belgica, , Volume: 80, Issue:4
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25, Issue:2, 2023
Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses.Journal of clinical pharmacology, , Volume: 63, Issue:6, 2023
A plain language summary on preventing fungal infections with isavuconazole in people with blood-related conditions.Future microbiology, , Volume: 18, 2023
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology, , Volume: 14, 2023
Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).Microbiology spectrum, , 02-23, Volume: 10, Issue:1, 2022
Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.Future microbiology, , Volume: 17, 2022
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-18, Volume: 72, Issue:10, 2021
Pulmonary infection secondary to Blastobotrys raffinosifermentans in a cystic fibrosis patient: Review of the literature.Mycoses, , Volume: 64, Issue:6, 2021
Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 26, Issue:11, 2020
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia.Mycopathologia, , Volume: 185, Issue:3, 2020
In vitro activity of isavuconazole against clinically isolated yeasts from Chile.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], , Volume: 51, Issue:4, 2020
Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.Medical mycology, , Oct-01, Volume: 58, Issue:7, 2020
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.Mycoses, , Volume: 62, Issue:1, 2019
Real-world use-Isavuconazole at a large academic medical center.Mycoses, , Volume: 62, Issue:6, 2019
Evaluation of isavuconazole MIC strips for susceptibility testing of Aspergillus and Scedosporium species.Medical mycology, , Jun-01, Volume: 57, Issue:4, 2019
Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.Diagnostic microbiology and infectious disease, , Volume: 92, Issue:1, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.Mycoses, , Volume: 61, Issue:7, 2018
Isavuconazole: is there a need for a new antifungal?The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Dosing of antifungal agents in obese people.Expert review of anti-infective therapy, , Volume: 14, Issue:2, 2016
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.Lancet (London, England), , Feb-20, Volume: 387, Issue:10020, 2016
Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.Journal of medical economics, , Volume: 19, Issue:7, 2016
Isavuconazole: a role for the newest broad-spectrum triazole.Lancet (London, England), , Feb-20, Volume: 387, Issue:10020, 2016
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 08-01, Volume: 63, Issue:3, 2016
Isavuconazonium sulfate (Cresemba)--a new antifungal.The Medical letter on drugs and therapeutics, , Mar-14, Volume: 58, Issue:1490, 2016
Isavuconazonium sulfate for the treatment of fungal infection.Drugs of today (Barcelona, Spain : 1998), , Volume: 52, Issue:1, 2016
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Expert review of anti-infective therapy, , Volume: 13, Issue:1, 2015
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:4, 2015
[NEW ANTIFUNGAL DRUGS FOR PREVENTION AND TREATMENT OF VISCERAL MYCOSES].La Revue du praticien, , Volume: 65, Issue:10, 2015
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and propDiagnostic microbiology and infectious disease, , Volume: 82, Issue:4, 2015
Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Future microbiology, , Volume: 10, Issue:5, 2015
The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Expert opinion on pharmacotherapy, , Volume: 16, Issue:10, 2015
In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Isavuconazonium sulfate approved for invasive fungal infections.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Apr-15, Volume: 72, Issue:8, 2015
Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.Journal of clinical microbiology, , Volume: 51, Issue:9, 2013
Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.Current opinion in investigational drugs (London, England : 2000), , Volume: 11, Issue:2, 2010
Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.Mycopathologia, , Volume: 170, Issue:5, 2010
In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.International journal of antimicrobial agents, , Volume: 36, Issue:4, 2010
[Recent advances in the study of new antifungal lead compounds].Yao xue xue bao = Acta pharmaceutica Sinica, , Volume: 45, Issue:8, 2010
In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.Medical mycology, , Volume: 47, Issue:1, 2009
In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.The Journal of antimicrobial chemotherapy, , Volume: 64, Issue:1, 2009
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.Future microbiology, , Volume: 3, Issue:6, 2008
[no title available]Therapeutische Umschau. Revue therapeutique, , Volume: 73, Issue:8
[Pharmacological profile of isavuconazole].Revista iberoamericana de micologia, , Volume: 35, Issue:4
Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome.American journal of otolaryngology, , Volume: 37, Issue:2
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-18, Volume: 72, Issue:10, 2021
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 24 Suppl 1, 2018
Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube.The Journal of antimicrobial chemotherapy, , Dec-01, Volume: 78, Issue:12, 2023
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.Mycoses, , Volume: 66, Issue:5, 2023
Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological MalignanciTherapeutic drug monitoring, , 10-01, Volume: 44, Issue:5, 2022
Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.Microbial pathogenesis, , Volume: 115, 2018
Disseminated mucormycosis.Intensive care medicine, , Volume: 45, Issue:10, 2019
Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.Microbial pathogenesis, , Volume: 115, 2018
Invasive mould infections in the ICU setting: complexities and solutions.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents.Current opinion in infectious diseases, , Volume: 29, Issue:4, 2016
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and propDiagnostic microbiology and infectious disease, , Volume: 82, Issue:4, 2015
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Journal of clinical microbiology, , Volume: 51, Issue:8, 2013
In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.Medical mycology, , Volume: 47, Issue:1, 2009
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:4, 2008
A Rare Case of Journal of investigative medicine high impact case reports, , Volume: 8
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 25, Issue:2, 2023
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 10-29, Volume: 75, Issue:9, 2022
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-18, Volume: 72, Issue:10, 2021
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia.Mycopathologia, , Volume: 185, Issue:3, 2020
Conidiobolus pachyzygosporus invasive pulmonary infection in a patient with acute myeloid leukemia: case report and review of the literature.BMC infectious diseases, , Jul-22, Volume: 20, Issue:1, 2020
Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients.Emerging infectious diseases, , Volume: 25, Issue:9, 2019
Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 25, Issue:4, 2019
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , Volume: 24 Suppl 1, 2018
Hepatic veno-occlusive disease during isavuconazole administration.Journal of chemotherapy (Florence, Italy), , Volume: 30, Issue:1, 2018
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:4, 2015
Isavuconazole treatment of a patient with disseminated mucormycosis.Journal of clinical microbiology, , Volume: 52, Issue:3, 2014
A Rare Case of Journal of investigative medicine high impact case reports, , Volume: 8
Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies.Clinical pharmacokinetics, , Volume: 62, Issue:12, 2023
Early attainment of isavuconazole target concentration using an increased loading dose in critically ill patients with extracorporeal membrane oxygenation.The Journal of antimicrobial chemotherapy, , Dec-01, Volume: 78, Issue:12, 2023
Comment on: Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.The Journal of antimicrobial chemotherapy, , 11-28, Volume: 77, Issue:12, 2022
Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation-authors' response.The Journal of antimicrobial chemotherapy, , 11-28, Volume: 77, Issue:12, 2022
Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.The Journal of antimicrobial chemotherapy, , 08-25, Volume: 77, Issue:9, 2022
Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:11, 2019
Invasive mould infections in the ICU setting: complexities and solutions.The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1, 2017
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:9, 2019
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:9, 2016
A Rare Case of Journal of investigative medicine high impact case reports, , Volume: 8
Safety/Toxicity (19)
| Article | Year |
|---|
A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.
Mycoses, , Volume: 66, Issue:9 | 2023 |
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.
Scientific reports, , 04-25, Volume: 13, Issue:1 | 2023 |
Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses.
Journal of clinical pharmacology, , Volume: 63, Issue:6 | 2023 |
Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study.
Therapeutic drug monitoring, , 04-01, Volume: 45, Issue:2 | 2023 |
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
Transplantation, , 03-01, Volume: 107, Issue:3 | 2023 |
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 29, Issue:2 | 2023 |
Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting.
Hematology (Amsterdam, Netherlands), , Volume: 27, Issue:1 | 2022 |
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects.
Clinical pharmacology in drug development, , Volume: 11, Issue:6 | 2022 |
Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).
Microbiology spectrum, , 02-23, Volume: 10, Issue:1 | 2022 |
Efficacy and safety of Isavuconazole for the treatment of invasive
Expert opinion on pharmacotherapy, , Volume: 23, Issue:5 | 2022 |
Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Medical mycology, , Oct-04, Volume: 59, Issue:10 | 2021 |
Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience.
Journal of pediatric hematology/oncology, , Volume: 42, Issue:4 | 2020 |
Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
Mycoses, , Volume: 62, Issue:3 | 2019 |
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.
Mycoses, , Volume: 62, Issue:1 | 2019 |
An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
Expert opinion on drug safety, , Volume: 16, Issue:3 | 2017 |
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:4 | 2015 |
A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:3 | 2015 |
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
Antimicrobial agents and chemotherapy, , Volume: 50, Issue:1 | 2006 |
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy
Antimicrobial agents and chemotherapy, , Volume: 50, Issue:1 | 2006 |
Long-term Use (1)
Pharmacokinetics (35)
| Article | Year |
|---|
Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube.
The Journal of antimicrobial chemotherapy, , Dec-01, Volume: 78, Issue:12 | 2023 |
High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints.
Clinical pharmacokinetics, , Volume: 62, Issue:12 | 2023 |
Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies.
Clinical pharmacokinetics, , Volume: 62, Issue:12 | 2023 |
Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC-MS/MS.
Thoracic cancer, , Volume: 14, Issue:33 | 2023 |
A Hybrid Algorithm Combining Population Pharmacokinetic and Machine Learning for Isavuconazole Exposure Prediction.
Pharmaceutical research, , Volume: 40, Issue:4 | 2023 |
Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses.
Journal of clinical pharmacology, , Volume: 63, Issue:6 | 2023 |
Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration.
Journal of veterinary internal medicine, , Volume: 36, Issue:4 | 2022 |
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects.
Clinical pharmacology in drug development, , Volume: 11, Issue:6 | 2022 |
Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects.
Antimicrobial agents and chemotherapy, , 08-17, Volume: 65, Issue:9 | 2021 |
Isavuconazole: Case Report and Pharmacokinetic Considerations.
Chemotherapy, , Volume: 63, Issue:5 | 2018 |
Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro.
Drug testing and analysis, , Volume: 11, Issue:4 | 2019 |
Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
Journal of clinical pharmacology, , Volume: 58, Issue:10 | 2018 |
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
Clinical pharmacokinetics, , Volume: 57, Issue:12 | 2018 |
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Journal de mycologie medicale, , Volume: 28, Issue:1 | 2018 |
Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation.
Transplant infectious disease : an official journal of the Transplantation Society, , Volume: 20, Issue:3 | 2018 |
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
European journal of drug metabolism and pharmacokinetics, , Volume: 43, Issue:3 | 2018 |
Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Jun-01, Volume: 64, Issue:11 | 2017 |
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1 | 2017 |
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
Antimicrobial agents and chemotherapy, , Volume: 60, Issue:9 | 2016 |
Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects.
Clinical pharmacology in drug development, , Volume: 6, Issue:1 | 2017 |
Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.
Clinical pharmacology in drug development, , Volume: 6, Issue:1 | 2017 |
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
Antimicrobial agents and chemotherapy, , Volume: 60, Issue:8 | 2016 |
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
The Journal of antimicrobial chemotherapy, , Volume: 71, Issue:7 | 2016 |
Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.
Antimicrobial agents and chemotherapy, , Volume: 60, Issue:5 | 2016 |
Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Antimicrobial agents and chemotherapy, , Volume: 60, Issue:5 | 2016 |
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Pharmacotherapy, , Volume: 35, Issue:11 | 2015 |
Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis.
Antimicrobial agents and chemotherapy, , Volume: 60, Issue:1 | 2016 |
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:4 | 2015 |
Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.
Antimicrobial agents and chemotherapy, , Volume: 57, Issue:12 | 2013 |
Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.
Antimicrobial agents and chemotherapy, , Volume: 57, Issue:11 | 2013 |
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
Expert opinion on drug metabolism & toxicology, , Volume: 8, Issue:6 | 2012 |
Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.
Antimicrobial agents and chemotherapy, , Volume: 53, Issue:11 | 2009 |
Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
Antimicrobial agents and chemotherapy, , Volume: 53, Issue:8 | 2009 |
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
Antimicrobial agents and chemotherapy, , Volume: 50, Issue:1 | 2006 |
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy
Antimicrobial agents and chemotherapy, , Volume: 50, Issue:1 | 2006 |
Bioavailability (16)
| Article | Year |
|---|
Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube.
The Journal of antimicrobial chemotherapy, , Dec-01, Volume: 78, Issue:12 | 2023 |
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.
Frontiers in cellular and infection microbiology, , Volume: 12 | 2022 |
Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration.
Journal of veterinary internal medicine, , Volume: 36, Issue:4 | 2022 |
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |
[Invasive aspergillosis in solid organ transplantation].
Revista iberoamericana de micologia, , Volume: 35, Issue:4 | |
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Journal de mycologie medicale, , Volume: 28, Issue:1 | 2018 |
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
European journal of drug metabolism and pharmacokinetics, , Volume: 43, Issue:3 | 2018 |
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1 | 2017 |
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Antimicrobial agents and chemotherapy, , Volume: 61, Issue:6 | 2017 |
Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.
International journal of clinical pharmacology and therapeutics, , Volume: 54, Issue:8 | 2016 |
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Pharmacotherapy, , Volume: 35, Issue:11 | 2015 |
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Nov-15, Volume: 61, Issue:10 | 2015 |
Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Future microbiology, , Volume: 10, Issue:5 | 2015 |
Newer antifungal agents.
Expert review of anti-infective therapy, , Volume: 9, Issue:3 | 2011 |
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
Antimicrobial agents and chemotherapy, , Volume: 50, Issue:1 | 2006 |
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy
Antimicrobial agents and chemotherapy, , Volume: 50, Issue:1 | 2006 |
Dosage (34)
| Article | Year |
|---|
Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube.
The Journal of antimicrobial chemotherapy, , Dec-01, Volume: 78, Issue:12 | 2023 |
Early attainment of isavuconazole target concentration using an increased loading dose in critically ill patients with extracorporeal membrane oxygenation.
The Journal of antimicrobial chemotherapy, , Dec-01, Volume: 78, Issue:12 | 2023 |
Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies.
Clinical pharmacokinetics, , Volume: 62, Issue:12 | 2023 |
PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.
CPT: pharmacometrics & systems pharmacology, , Volume: 12, Issue:6 | 2023 |
Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses.
Journal of clinical pharmacology, , Volume: 63, Issue:6 | 2023 |
Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , 07-22, Volume: 79, Issue:15 | 2022 |
Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignanci
Therapeutic drug monitoring, , 10-01, Volume: 44, Issue:5 | 2022 |
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 28, Issue:6 | 2022 |
Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.
Medical mycology, , Oct-01, Volume: 58, Issue:7 | 2020 |
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-18, Volume: 72, Issue:10 | 2021 |
Isavuconazole Kinetic Exploration for Clinical Practice.
Drugs in R&D, , Volume: 18, Issue:4 | 2018 |
Drug-Drug Interaction Between Isavuconazole and Tacrolimus: Is Empiric Dose Adjustment Necessary?
Journal of pharmacy practice, , Volume: 33, Issue:2 | 2020 |
Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.
Pediatric blood & cancer, , Volume: 65, Issue:10 | 2018 |
Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
Journal of clinical pharmacology, , Volume: 58, Issue:10 | 2018 |
Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.
Mycoses, , Volume: 61, Issue:3 | 2018 |
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
European journal of drug metabolism and pharmacokinetics, , Volume: 43, Issue:3 | 2018 |
Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.
The Journal of antimicrobial chemotherapy, , Jan-01, Volume: 73, Issue:1 | 2018 |
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Antimicrobial agents and chemotherapy, , Volume: 61, Issue:12 | 2017 |
Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum.
Therapeutic drug monitoring, , Volume: 39, Issue:5 | 2017 |
New pharmacological opportunities for the treatment of invasive mould diseases.
The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1 | 2017 |
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
The Journal of antimicrobial chemotherapy, , 03-01, Volume: 72, Issue:suppl_1 | 2017 |
An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
Expert opinion on drug safety, , Volume: 16, Issue:3 | 2017 |
Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.
International journal of clinical pharmacology and therapeutics, , Volume: 54, Issue:8 | 2016 |
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
Antimicrobial agents and chemotherapy, , Volume: 60, Issue:8 | 2016 |
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
The Journal of antimicrobial chemotherapy, , Volume: 71, Issue:7 | 2016 |
Isavuconazonium sulfate for the treatment of fungal infection.
Drugs of today (Barcelona, Spain : 1998), , Volume: 52, Issue:1 | 2016 |
Dosing of antifungal agents in obese people.
Expert review of anti-infective therapy, , Volume: 14, Issue:2 | 2016 |
In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12 | 2015 |
Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Future microbiology, , Volume: 10, Issue:5 | 2015 |
Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
The Annals of pharmacotherapy, , Volume: 49, Issue:7 | 2015 |
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:4 | 2015 |
A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:3 | 2015 |
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.
The Journal of antimicrobial chemotherapy, , Volume: 63, Issue:1 | 2009 |
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
Antimicrobial agents and chemotherapy, , Volume: 50, Issue:1 | 2006 |
Interactions (6)
| Article | Year |
|---|
Isavuconazole-tacrolimus drug-drug interactions in HSCT patients.
The Journal of antimicrobial chemotherapy, , 10-03, Volume: 78, Issue:10 | 2023 |
In vitro synergy of isavuconazole in combination with colistin against Candida auris.
Scientific reports, , 12-08, Volume: 10, Issue:1 | 2020 |
Drug-Drug Interaction Between Isavuconazole and Tacrolimus: Is Empiric Dose Adjustment Necessary?
Journal of pharmacy practice, , Volume: 33, Issue:2 | 2020 |
Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.
Journal de mycologie medicale, , Volume: 28, Issue:2 | 2018 |
Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects.
Clinical pharmacology in drug development, , Volume: 6, Issue:1 | 2017 |
Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.
Clinical pharmacology in drug development, , Volume: 6, Issue:1 | 2017 |